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Function of latent membrane protein 2B in EBV-positive
Burkitt's lymphoma
Abstract
Epstein-Barr virus (EBV) is a human γ-herpesvirus that, following primary infection, persists latently in
the host's memory B-cell pool for life and may periodically reactivate to lytic EBV is linked to
malignancies including Burkitt's lymphoma (BL), Hodgkin's lymphoma (HL), and post-transplant
lymphoproliferative diseases where it expresses different of latency genes. Among these genes, latent
membrane protein (LMP)2A and LMP2B seem to be involved in the regulation of EBV latency.
LMP2A blocks the signalling from the B-cell receptor (BCR) after its engagement, which results
otherwise in switching from latent to lytic EBV infection and induction of apoptosis. Therefore, LMP2A
contributes to ensuring the persistence of EBV in the latently infected B-cell. By contrast, the function
of LMP2B, a splice variant of LMP2A, and its interaction with LMP2A is still not resolved. Thus, the
investigation of the function of LMP2B and its contribution to latent and lytic EBV infection was the
main goal of my PhD thesis. To study switching of latent to lytic EBV the EBV-harboring BL cell line
Akata was employed. BL Akata cells can easily be induced to switch latent to lytic EBV upon
engagement of their BCR through cross-linking using anti-human immunoglobulin antibodies. BL
Akata cells with silenced LMP2A, silenced LMP2B, overexpressed LMP2A, or overexpressed LMP2B
were generated. The establishment of these cell lines revealed for the first time that silencing of LMP2B
in EBV-harboring BL cells resulted in reduced expression of the initiator of lytic EBV, i.e.,
immediate-early lytic BZLF1 EBV gene mRNA and late lytic gp350/220 protein upon BCR
cross-linking. Similarly, reduction of lytic EBV activation was observed in BL Akata cells
overexpressing LMP2A. By contrast, silencing of LMP2A and LMP2B overexpression in BL Akata
cells resulted in higher lytic EBV mRNA and protein expression upon BCR crosslinking. We could
further demonstrate that LMP2A and LMP2B physically interact and that LMP2B resides predominantly
in intracellular compartments, whereas LMP2A was detected on the plasma membrane as well as in
intracellular compartments. In conclusion, these observations indicate a role for LMP2B distinct from
LMP2A in regulation of lytic EBV activation in the host cell and support the hypothesis that LMP2B
exhibits a negative regulatory effect on the ability of LMP2A to maintain latent EBV by preventing the
switch to lytic EBV.
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41. Summary
Epstein-Barr virus (EBV) is a human γ-herpesvirus that, following primary infection, persists 
latently in the host’s memory B-cell pool for life and may periodically reactivate to lytic 
infection. EBV is linked to malignancies including Burkitt’s lymphoma (BL), Hodgkin’s 
lymphoma (HL), and post-transplant lymphoproliferative diseases where it expresses different 
patterns of latency genes. Among these genes, latent membrane protein (LMP)2A and 
LMP2B seem to be involved in the regulation of EBV latency. LMP2A blocks the signalling 
from the B-cell receptor (BCR) after its engagement, which results otherwise in switching 
from latent to lytic EBV infection and induction of apoptosis. Therefore, LMP2A contributes 
to ensuring the persistence of EBV in the latently infected B-cell. By contrast, the function of 
LMP2B, a splice variant of LMP2A, and its interaction with LMP2A is still not resolved. 
Thus, the investigation of the function of LMP2B and its contribution to latent and lytic EBV 
infection was the main goal of my PhD thesis.
To study switching of latent to lytic EBV the EBV-harboring BL cell line Akata was
employed. BL Akata cells can easily be induced to switch latent to lytic EBV upon 
engagement of their BCR through cross-linking using anti-human immunoglobulin 
antibodies. BL Akata cells with silenced LMP2A, silenced LMP2B, overexpressed LMP2A, or
overexpressed LMP2B were generated.
The establishment of these cell lines revealed for the first time that silencing of LMP2B in 
EBV-harboring BL cells resulted in reduced expression of the initiator of lytic EBV, i.e., 
immediate-early lytic BZLF1 EBV gene mRNA and late lytic gp350/220 protein upon BCR 
cross-linking. Similarly, reduction of lytic EBV activation was observed in BL Akata cells 
overexpressing LMP2A. By contrast, silencing of LMP2A and LMP2B overexpression in BL 
Akata cells resulted in higher lytic EBV mRNA and protein expression upon BCR cross-
linking. We could further demonstrate that LMP2A and LMP2B physically interact and that 
LMP2B resides predominantly in intracellular compartments, whereas LMP2A was detected 
on the plasma membrane as well as in intracellular compartments.
In conclusion, these observations indicate a role for LMP2B distinct from LMP2A in 
regulation of lytic EBV activation in the host cell and support the hypothesis that LMP2B 
exhibits a negative regulatory effect on the ability of LMP2A to maintain latent EBV by 
preventing the switch to lytic EBV.
52. Zusammenfassung
Das Epstein-Barr Virus (EBV) ist ein humanes γ-Herpesvirus, welches nach der
Primärinfektion eine lebenslange, latente Infektion in memory B Zellen etabliert und 
periodisch in seine lytische Form wechseln kann. EBV wird mit verschiedenen Malignomen 
assoziiert, unter anderem mit dem Burkitt’s Lymphom (BL), dem Hodgkin’s Lymphom (HL) 
und der lymphoproliferativen Krankheiten nach Organtransplantation, in denen das Virus
unterschiedliche Expressionsmuster der Latenzgene aufweist. Unter diesen Genen befindet 
sich das Latente Membran Protein (LMP)2A und LMP2B, welche die lytische und latente 
Form von EBV zu regulieren scheinen. LMP2A blockiert die Signalkaskade welche vom B 
Zell Rezeptor nach dessen Aktivierung durch ein fremdes Antigen ausgelöst wird. Die 
Signalkaskade würde im Normalfall zur Induktion der lytischen Form von EBV führen und 
letztendlich in Apoptose enden. Deshalb stellt LMP2A die Aufrechterhaltung des latenten 
Zustandes von EBV sicher. Andererseits ist über die Funktion von LMP2B, einer 
Splicevariante von LMP2A, wenig bekannt. Das Hauptziel meines PhD Projektes war nun, 
die Funktion von LMP2B zu definieren und seinen Beitrag zur latenten und lytischen EBV 
Infektion zu untersuchen.
Um die Aktivierung von latentem zu lytischem EBV zu studieren, wurde die EBV-positive 
BL Zelllinie Akata verwendet. BL Akata Zellen können leicht stimuliert werden, indem der B 
Zell Rezeptor mit spezifischen menschlichen Immunglobulinen aktiviert wird, was zur 
Induktion von lytischem EBV führt. Deshalb wurden BL Akata Zellen mit gesilenztem
LMP2A, gesilenztem LMP2B, überexprimiertem LMP2A und überexprimiertem LMP2B
etabliert.
Diese Zelllinien ermöglichten zum ersten Mal zu demonstrieren, dass durch gesilenztes 
LMP2B die lytische Aktivierung von EBV vermindert werden konnte. Als read-out 
bestimmten wir die mRNA Expression des initialen lytischen EBV Genes BZLF1 und die 
Proteinmenge des viralen Hüllenproteins gp350/220 nach B Zell Rezeptor Stimulation.
Vergleichsweise führte die Überexpression von LMP2A zu verminderter lytischen EBV 
Aktivierung in BL Akata Zellen. Anderseits resultierte das Silenzing von LMP2A und die 
Überexpression von LMP2B in BL Akata Zellen nach Stimulation in höheren lytischen EBV 
mRNA- und Proteinlevels. Des Weiteren wurde gezeigt, dass LMP2A und LMP2B 
physikalisch interagieren und dass LMP2B hauptsächlich in intrazellulären Kompartimenten 
vorkommt, während LMP2A auf der Plasmamembran sowie in intrazellulären 
Kompartimenten detektiert wurde.
6Diese Beobachtungen lassen auf eine unterschiedliche Rolle von LMP2B in der Regulation 
von lytischem und latentem EBV im Vergleich zu LMP2A schliessen und unterstützt die 
Hypothese, dass LMP2B einen negativ regulatorischen Effekt auf LMP2A und dessen 
Funktion in der Aufrechterhaltung des latenten Zustandes von EBV aufweist. 
73. Introduction
3.1 Tumor viruses
Virus infection and tumor formation have been associated for the first time in 1910 by Peyton 
Rous. He could demonstrate that filtered cell supernatant derived from a chicken sarcoma 
induced new sarcoma formation in a healthy chicken. The sarcoma inducing agent was then 
termed Rous sarcoma virus (RSV). The identification of other viruses which induce tumor 
formation took almost a half of a century, i.e., the Shope virus causing papillomas in rabbits 
which was later found to be related to the human papilloma virus (HPV). The latter is known 
to cause cervical cancer, and a vaccine against HPV has most recently been licensed 1.
Intensive studies in the recent decades revealed that almost 15% of human cancers are 
associated to various types of viral infections, including retro-viruses, non-retroviral RNA 
viruses and DNA viruses 2 (Table 1). However, in many cases it is hard to pinpoint the cancer 
to a specific virus infection because the causal evidence can only be obtained after, e.g., 
immunization against a specific virus resulting in a significant reduced tumor incidence. Best 
reported are the vaccinations against Hepatitis B virus (HBV) for prevention of hepatocellular 
carcinoma or as mentioned above against HPV 1, 3. 
A hallmark of cancer is the continuous proliferation of cells, lacking any restrictive control of 
growth 4. The outgrowth of such a cell sub-population is caused by many factors, including 
genetical and environmental factors, to which the virus tumors belong. Among the genetical 
diseases linked to cancer are hereditary mal-functions of cellular genes resulting in, e.g., loss 
of tumor suppressors as described in retinoblastoma or breast cancer 5, 6. However, there are 
more cancers associated with aberrations in somatic cells acquired during time depending on 
environmental factors. Among these environmental factors, infections with viruses are the 
second highest risk factor for cancer development after tobacco consumption 7.
The mechanisms how viruses can contribute to tumor formation are multi-faceted. Many 
viruses establish persistent infections and cancer may occur as an accidental side effect of the 
long-term interaction of the virus and the host cell 7. Therefore, other risk factors must be 
taken into account, proposed as a triad function composed by viral infection, a co-carcinogen 
and a defective immune response leading finally to tumor formation. Furthermore, the impact 
of viral infections may be either indirect, by the continuous interaction of the virus and the 
host implicating chronic inflammation (HBV, Hepatitis C virus (HCV)), alteration of the 
immune response, and accumulation of mutations in infected cells or direct, manifested by the 
expression of viral oncogenes (v-onc) driving cell proliferation and malignant transformation.
8Well studied viral oncogenes directly affecting cell proliferation and transformation are for 
example the Tax protein from the human T-cell leukemia virus 1 (HTLV-1) or the latent 
membrane protein(LMP)1 from Epstein-Barr virus (EBV) 8, 9. 
Table 1: Characteristics of Human Oncogenic Viruses and their associated pathologies. 
Adapted from Boccardo and Villa.
Virus Family/Genus Genome Target cell Associated 
diseases
Associated 
cancers
Epstein-Barr Virus (EBV) Herpesviridae/Lymphocryptovirus dsDNA B-lymphocytes, 
Oropharyngeal 
epithelial cells
Table 3 Table 3
Kaposi’s sarcoma 
Herpesvirus (KSHV)
Herpesviridae/ Rhadinovirus dsDNA Endothelial cells, 
Lymphocytes
Skin lesions, 
Heary 
leukoplakia
Kaposi sarcoma
Human T-cell leukemia 
virus (HTLV-I)
Retroviridae/Deltaretrovirus ssRNA T-lymphocytes Uveitis, 
Infective 
dermatitis
ATL
Human 
Immunodeficiency Virus 
(HIV)
Retroviridae/Lentivirus ssRNA CD4+ T-cells AIDS ARL, HD, MM
Hepatitis B Virus (HBV) Hepadnaviridae/Orthohepadnavirus dsDNA Hepatocytes Hepatitis, 
cirrhosis
Hepatocellular 
carcinoma
Hepatitis C Virus (HCV) Flaviviridae/Hepacivirus ssRNA Hepatocytes Hepatitis, 
cirrhosis
Hepatocellular 
carcinoma
Human Papillomavirus 
(HPV)
Papillomaviridae/k-papillomavirus dsDNA Mucosal and 
Cutaneous 
squamous 
epithelial cells
Condyloma 
acuminate, 
Common 
warts
Ano-genital 
carcinomas, 
cutaneous 
carcinoma
ATL: adult T-cell leukemia; AIDS: Acquired Immunodeficiency syndrome; ARL: AIDS related lymphomas (includes Burkitt’s lymphoma, 
diffuse large B-cell lymphoma, Post-transplant lymphoproliferative disorder like B-cell lymphomas); HD: Hodgkin’s lymphoma; MM: 
Multiple myeloma.
Astonishingly, EBV is present in more than 90 % of healthy individuals of the world’s
population 10, 11, creating an enigma about the pathology of EBV infection. EBV has been
linked to non-Hodgkin’s and Hodgkin’s lymphomas 12 but the incidence is far below the 
expected malignant impact of a powerful oncogenic virus. Thus, the term of EBV as an
oncogenic virus has been challenged and revised. EBV is actually one of the most successful 
viruses because (i) it does not kill its host cell but establishes a latent infection and (ii) the 
infected cells expressing oncogenic genes as LMP1 are erased by the immune system in that 
way preventing the outgrowth of tumors and harm to the host. This was supported by the 
findings that after EBV infects a B cell, initial expression of LMP1 is shut down and latency 
is established 13. Furthermore, occasional switch to another viral latency state of EBV
9includes the expression of LMP1 with subsequent initiation of specific cytotoxic T-cell killing
in healthy individuals 14. Additionally, tumor cells containing EBV emerge in EBV positive 
patients after treatment with immunosuppressive drugs or in association with HIV infection
reflecting the loss of immunosurveillance and the capability of malignant transformation by 
viral oncogenes. Thus, taken together these facts, malignancies associated with EBV infection 
seem to be an unwanted side effect of the virus. Nevertheless, EBV positive tumors represent 
a life threatening disease and host-pathogen interaction need careful investigation for effective 
intervention and cure.
In the following paragraphs, EBV infection and its contribution to lymphomagenesis is 
described.
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4. Epstein-Barr Virus infection and lymphomagenesis
4.1 Epstein-Barr Virus
The Epstein-Barr virus (EBV) is a B-lymphotropic -herpesvirus which was discovered by the 
British scientists Epstein, Achong and Barr in cells cultured from endemic Burkitt’s 
lymphoma (eBL) tissue by electron microscopy in 1964 15. Endemic BL was then diagnosed
in more than 95 % of observed cases EBV positive and was found to be located
predominantly in sub-Saharan Africa where malaria infection represents one of the major 
illnesses 16. Subsequent epidemiologic investigations revealed that EBV infects more than 
90% of the human population 10, 11. Primary infection with EBV is transmitted via saliva and 
acquired mostly during childhood and adolescence, and may go unrecognized or manifest as 
infectious mononucleosis (IM), a febrile illness characterized by tonsillopharyngitis, and
generally enlarged lymph nodes, liver and spleen.
4.2 Latency programs of EBV at and after primary infection
Primary infection occurs in the oropharynx where EBV replicates in epithelial and B cells. 
After primary infection, EBV establishes a latent infection in the memory B-cell pool where 
its linear DNA is circularized in the nucleus 17.
Depending on the differentiation stage of the newly infected B cell, different EBV gene 
expression pattern/programs can be observed (Figure 1; Table 2). The Growth program is 
defined as the EBV expression pattern detected when EBV infects mature/naïve B-cells 
(EBNA1-6 (EBV nuclear antigen), LMP1 (latent membrane protein 1), LMP2A, LMP2B, and 
EBERs (EBV-encoded RNA)) and drives the B-cell towards proliferation and a germinal 
center (GC) reaction 10. In these GC B-cells, the Default program is predominantly switched 
on, comprised by the expression of EBNA1, LMP1, LMP2A, LMP2B, and EBERs which 
forces proliferation and differentiation to a memory B-cell. Upon completing differentiation, 
either from an initially infected mature/naïve or GC B-cell, the infected memory B-cells enter 
the periphery 10.
After establishment of a latent infection in the memory B-cell pool, EBV can be detected in 1 
to 50 cells per 106 circulating B-cells 18, 19. In these circulating memory B-cells, resting 
(Latency 0) and dividing (Latency I) memory B-cells can be distinguished by the EBV gene
expression of EBERs only and EBERs, EBNA1, and occasionally LMP2A, respectively 10. 
EBERs are small non-coding RNAs, which are abundantly expressed in the infected B-cell 20. 
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EBER1 is highly structured and inhibits protein kinase R (PKR) which is involved in the 
control of protein synthesis at the level of polypeptide chain initiation and cell death 21, 22.  
EBNA1 is expressed for the replication of the EBV genome and the episomal segregation to 
the daughter cell at cell division. The function of LMP2A in the context of dividing memory 
B-cells is not yet fully understood.
Figure 1: Models for EBV infecting B cells in distinct differential stages
Figure 1: A: Infection of a naïve/mature B-cell with EBV. EBV initiates a germinal centre (GC) reaction and terminal differentiation into a 
memory B-cell. B: Direct infection of a GC B-cell by EBV and subsequent terminal differentiation into a memory B-cell. C: Direct infection 
of a memory B-cell by EBV. A, B, and C lead to the establishment of a latently infected memory B-cell pool. © by M. Dorner
Table 2: Patterns of EBV gene expression depending on B cell differential state
Gene expression 
program
EBNA1 EBNA2-6, 
EBNA-LP
LMP1, LMP2A, 
LMP2B
EBER1, EBER2 Site of infection
Growth program + + + + Mature/naive B-cell, Epithelial cells
Default program + + + GC B-cell
Latency 0 - - - + Resting memory B-cell
Latency I + - LMP2 only + Dividing memory B-cell
GC: germinal centre
If LMP2A is not able to rescue the activated memory B-cell due to too strong stimuli by the 
antigen, the lytic program of EBV is switched on. The expression of all EBV lytic genes in
plasma cells leads to replication and production of new EBV particles which are released 
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following lysis and death of the infected cell 14. The virions are then shed in the saliva and 
able to infect new hosts.
4.3 Latency programs of EBV in lymphomagenesis
EBV has ever since its discovery in 1964 been associated with various lymphomas and 
cancers. These include lymphomas of B, T and natural killer (NK) cell origin such as the 
immunoblastic lymphoma of immunosuppressed, endemic Burkitt’s lymphoma (BL), 
Hodgkin's lymphoma (HL), and nasal T/NK lymphoma, but also lymphoepitheliomas of the 
nasopharynx, thymus and stomach and leiomyosarcomas arising in organ transplant patients 
and HIV-infected individuals summarized in table 3 12.
Table 3: Patterns of EBV gene expression in latency and associated pathologies
Latency 
program
EBNA1 EBNA2-6, 
EBNA-LP
LMP1, LMP2A, 
LMP2B
EBER1, 
EBER2
Associated cancer (EBV positivity)
Latency I + - - + Burkitt’s lymphoma (en. >95%; non-en.: 15-30%)
Latency II + - + + Hodgkin’s lymphoma (mc: 70%; ld: >95%; ns: 10-40%)
Nasopharyngeal carcinoma (>95%)
Peripheral T/NK lymphoma (> 90%)
Latency III + + + + AIDS-associated lymphomas (> 90%)
Post-transplant lymphoproliverative disorders (>90%)
EBNA, EBV nuclear antigen; LP, latent protein; LMP, latent membrane protein; EBER, EBV non-polyadenylated RNA; mc: mixed 
cellularity; ld: lymphocyte depleted; nc: nodular sclerosing
Not all latent EBV genes are always simultaneously expressed in the different pathological 
situations. Three distinct expression patterns seem to allow EBV to manipulate the host cell 
which lead to the formation of lymphomas or cancer while escaping immune recognition by 
the host 23, 24. The Latency I program is found in BL where the only EBV genes expressed are 
EBNA1 and the EBERs. This EBV expression pattern resembles the one detected in dividing 
memory B-cells of healthy carriers as described in Table 2. The Latency II program expresses 
EBNA1 plus LMP1, LMP2A, LMP2B, and EBERs and is associated with HL, 
nasopharyngeal carcinoma (NPC), and peripheral T/NK lymphoma 12. The Latency III
program involves expression of all six EBNAs, the LMPs (1, 2A, 2B), and EBERs and is 
found in immunocompromized hosts including posttransplant lymphoproliferative diseases 
(PTLD) and AIDS-associated lymphomas 25. As EBV latency III resembles the EBV 
expression pattern of the Growth program it would normally elicit T-cell response and 
eradication of the tumorigenic memory B-cells. Thus, in individuals with an intact immune 
system no EBV-positive B-cells expressing Latency III are detected.
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4.4 EBV and Burkitt’s lymphoma
The hallmark of all BLs is the reciprocal translocation of c-myc and an immunoglobulin gene, 
most often between chromosomes 8 and 14, which places c-myc under the control of Ig 
transcription-controlling promoter and enhancer sequences 26. This translocation leads to a 
continuous high expression of c-myc in B-cells, driving proliferation and favours tumor 
formation. Cells normally undergo apoptosis when c-myc reaches a certain threshold 27. Thus, 
there is a selection for other mutations, abrogating the apoptosis-inducing signals. Such 
mutations are found in direct p53 inactivation or in other key players involved in the p53 
pathway 28, 29.
The role of EBV in pathogenesis of BL has been widely discussed. Although c-myc
translocation is the major event leading to tumor formation, it seems that EBV favours the 
translocation. There have been reports of EBV increasing genomic instability 30-33. Moreover, 
EBV starts its ‘Growth program’ after infecting a B cell, which increases proliferation rates, 
allowing fast replication cycles in the initial infection before shutting-down its gene 
expression and establishment of the latent infected B-cell pool. Additionally, EBV increases 
the probability of translocations on the one hand by the initiation of a GC reaction and on the 
other hand in the prevention of lytic EBV infection in activated memory B-cells encountering 
their specific antigen in the periphery, both inducing higher proliferation rates. According to 
the infection of B-cells in distinct differentiation states described above, there are as well 
reports of BL biopsies which comprise B cells phenotypically linked to GC or memory B-
cells.
Concerning these facts, BL might be derived from a memory B-cell in which EBV is found in 
its Latency state I as described above. Thus, it represents a model to study infected, dividing 
memory B-cells and the pathology of EBV controlling the switch from latent to lytic EBV 
infection. Due to the fact that the BL cell line Akata shows adequate activation of lytic EBV 
infection after BCR cross-linking with anti-IgG 34, 35, this cell line is an optimal model system 
as close as possible to the in vivo situation for investigating the impact of LMP2A and 
LMP2B in the maintenance of latent and lytic EBV infection.
Endemic BL accounts for up to 74 % of childhood malignancies in the African equatorial belt 
where it is as well associated with malaria infection 26, 36. Whereas endemic BL is in most 
cases comprised of EBV positive B cells, sporadic BL contains in 15-30 % of the cases EBV 
positive tumor cells (Table 3). BL characteristically involves the jaw or other facial bones, 
ovaries, kidney or the breast. Because of the rapid rate of tumor growth in BL, it is important 
to begin treatment as soon as possible after diagnosis. Bulky abdominal tumors or chest 
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tumors are sometimes removed surgically before the patient begins chemotherapy or radiation 
therapy. Untreated BL is often followed by rapid death of the patient. Today, BL is treated 
with a short course of high-dose chemotherapy, usually with cyclophosphamide (Endoxan), a 
drug that is converted in vivo into two active compounds which interfere with DNA and 
replication, in combination of methotrexate (purine and pyrimidine synthesis inhibitor), 
vincristine (mitotic spindle formation inhibitor), prednisone (steroid; immunosuppressive), 
and doxorubicin (replication inhibitor; DNA intercalating).
The sensibility of BL to combination chemotherapies is greater the more localized the tumor 
is. Once the tumor expanded to the bone marrow or the central nervous system (CNS) the cure 
rate decreases dramatically. Although the cytotoxic drugs exhibit collateral effects by killing 
healthy cells, the cure rate nowadays is more than 50%.
4.5 EBV and Hodgkin’s lymphoma
HL is a type of lymphoma first described by Thomas Hodgkin in 1832 defined as a malignant 
disorder in which there is progressive (but painless) enlargement of lymph tissue followed by 
enlargement of the spleen and liver. HL can be divided into four subtypes defined by their 
histological pattern which are summarized in table 3. HL is characterized clinically by spread 
of disease from one lymph node to another and by the development of systemic symptoms as 
fever or weight loss. The incidence of new HL arising a year lies between 2 and 4 per 100’000
inhabitants. The tumor of HL comprises only about 1-2% malignant cells which are named 
Reed Sternberg cells (RSC). The fast majority of the tumor mass is from cells activated due to 
continuous inflammation and cytokine secretion, i.e., macrophages, T-cells, and granulocytes.
The RSCs are derived from B cells. Due to the fact, that only 1-2 % of tumor cells are 
responsible for the tumor formation, the isolation and characterization of these cells has been 
extremely difficult. Recently, it has been postulated that EBV associated HL contains B-cells 
with crippled and non-functional BCRs which then result in the malignant RSCs 37, 38. 
Moreover, the RSCs in HL were defined by their surface immunoglobulin expression pattern, 
as GC B-cells and due to viral LMP2A, LMP2B and LMP1 expression to belong to the EBV 
Latency program II. For more detailed information how LMP2A and LMP2B are 
interconnected with HL, please refer to section 4.7.
HL was one of the first cancers to be cured by radiation and subsequently by combination 
chemotherapy. Currently, ABVD chemotherapy is the gold standard for treatment of HL. The 
abbreviation stands for the four drugs doxorubicin, bleomycin (induction of DNA strand 
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brakes), vinblastine (mitotic inhibitor), and dacarbazine (alkylating DNA agent). The cure rate 
is about 93%, making it one of the most curable forms of cancer.
4.6 Inducers of lytic EBV infection in vitro
Activation of the lytic infection can be initiated by a variety of agents in culture, including 
anti-immunoglobulin, calcium ionophore, sodium-butyrate and the phorbol ester 12-O-
tetradecanyl-phorbol-13-acetate (TPA) summarized in Table 4. These agents exhibit 
considerable variability in the degree of activation of lytic EBV infection in established EBV-
infected cell lines. Anti-IgG, as described above, and anti-IgM stimulation showed a high 
activation of lytic EBV infection in the BL cell lines Akata and Ramos, respectively 34. 
Induction of lytic EBV infection using various compounds including 5-Azacytidine and 
dexamethasone is increasingly being explored as a potential treatment of EBV-carrying 
malignancies, but the use of these compounds may be burdened or limited by toxic side 
effects 39-42. 
Table 4: Inducers of lytic EBV infection in vitro
Agent Mode of action Reference
anti-immunoglobulin BCR cross-linking 35, 43
calcium ionophore A23187 Calcium flux induction 44
Doxorubicin DNA interference 44, 45
cis-platin DNA interference 44
Methotrexate Metabolic inhibitor 46
Gemcitabine Cytidine analogue 45
TPA Phorbol ester; PKC activator 43
TGF-β Not known 43
Dexamethasone Glucocorticoid 40
5-Azacytidine DNMTI 11, 47, 48
sodium-butyrate Histone deacetylase inhibitor 11, 48
Trichostatin A Histone deacetylase inhibitor 49
TPA: 12-O- tetradecanyl-phorbol-13-acetate; DNMTI: DNA methyl transferase inhibitor
Among the DNA methyl transferase inhibitors (DNMTI), the recently discovered Zebularine 
is the most promising. The advantages of Zebularine lies in its long half-life and stability 50, 51. 
Additionally, it is well tolerated in far higher concentrations than for example the more toxic 
5-Azacytidine 52. Moreover, it has been demonstrated that its administration switches silenced 
genes on by demethylation and kills specifically tumor cells 53. Thus, the impact of Zebularine 
on EBV infected BL cells might represent a powerful tool as the genome of EBV in BLs is 
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hypermethylated. Demethylation might lead to lytic EBV infection resulting in tumor cell 
death.
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4.7 Viral and cellular sensors for latent EBV disruption
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Abstract
The oncogenic Epstein-Barr virus (EBV) infects the majority of the human population and 
establishes a life-long latent infection in B cells from which the virus may reactivate 
periodically. To cope with these prerequisites, EBV hijacks B-cell differentiation pathways 
using on the one hand own viral genes interfering with B-cell signalling to establish latent 
infection for life-long persistence and on the other hand cellular genes as sensors for the 
switch of latent to lytic EBV infection. A prominent protein is the viral latent membrane 
protein (LMP)2A which is believed to play a crucial role in the maintenance of latent EBV by 
blocking activation of its host cell and by providing a surrogate B-cell receptor (BCR) signal 
essential for cell survival 1, 2. These two functions of LMP2A demand a tight control of 
LMP2A activity and expression levels. Recent insights in LMP2B 3-5, an isoform of LMP2A, 
prompt us to hypothesize that LMP2B modulates the activity of LMP2A and regulates in that 
way activation of lytic EBV infection. Another gene terminating latent EBV infection is the 
cellular factor X-box binding protein (XBP)-1 which is upregulated during terminal plasma 
cell differentiation and increases the transcription of the master EBV lytic regulator gene 
BZLF1 6, 7. In this review we summarize the latest findings of EBV hijacking the normal B-
cell differentiation pathways.
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Viral and cellular sensors for latent EBV disruption
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The oncogenic Epstein-Barr virus (EBV) infects the majority of the human population 
and establishes a life-long latent infection in B cells from which the virus may reactivate 
periodically. To cope with these prerequisites, EBV hijacks B-cell differentiation 
pathways using on the one hand own viral genes interfering with B-cell signalling to 
establish latent infection for life-long persistence and on the other hand cellular genes as 
sensors for the switch of latent to lytic EBV infection. A prominent protein is the viral 
latent membrane protein (LMP)2A which is believed to play a crucial role in the 
maintenance of latent EBV by blocking activation of its host cell and by providing a 
surrogate B-cell receptor (BCR) signal essential for cell survival 1, 2. These two functions 
of LMP2A demand a tight control of LMP2A activity and expression levels. Recent 
insights in LMP2B 3-5, an isoform of LMP2A, prompt us to hypothesize that LMP2B 
modulates the activity of LMP2A and regulates in that way activation of lytic EBV 
infection. Another gene terminating latent EBV infection is the cellular factor X-box 
binding protein (XBP)-1 which is upregulated during terminal plasma cell 
differentiation and increases the transcription of the master EBV lytic regulator gene 
BZLF1 6, 7. In this review we summarize the latest findings of EBV hijacking the normal 
B-cell differentiation pathways.
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Epstein–Barr virus (EBV) is a ubiquitous human gammaherpesvirus linked to many 
malignancies including Burkitt’s lymphoma (BL) and Hodgkin’s lymphoma (HL) 8, 9. After 
primary infection, EBV enters the memory B-cell pool establishing a life-long latent infection 
from which lymphomas might arise 1, 10. Once in its latent form, EBV persists as an episome 
in the nucleus. The EBV genome is maintained by segregation of its episome to the daughter 
cell after mitotic cell division. Occasionally, there is activation of lytic EBV infection which 
leads to the production of infectious particles and host cell death. EBV hijacks B cells at 
specific stages of B-cell differentiation and uses on the one hand own viral genes for 
manipulation of signalling pathways in the B cell and on the other hand cellular genes as 
sensors for the switch of latent to lytic EBV infection. Whether these rare events of activation 
are triggered by the virus, host cell factors, or both acting synergistically remains to be 
resolved.
In this review, we will focus on the viral gene LMP2 and the cellular gene XBP-1 and their
impact on B-cell differentiation pathways and latent and lytic EBV infection. Moreover, we 
will especially pay regard to the expression of LMP2B and LMP2A in different cellular 
compartments, propose a model of interaction and regulation of each other, and outline their 
possible functions in B-cell differentiation.
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1. EBV: hijacker of B-cell differentiation pathways
EBV hijacks B cells at specific stages of B-cell differentiation and uses on the one hand own 
viral genes for manipulation of signalling pathways in the B cell and on the other hand viral 
and cellular genes as sensors for the switch of latent to lytic EBV infection.
B-cell development can be divided into three main stages depending on localization 11: (i) 
primary lymphoid tissue (bone marrow), (ii) germinal centre, and (iii) blood and secondary 
lymphoid tissue. The B cells present in the bone marrow can be further subdivided into pro-, 
and pre- B-cells. Pro- B-cells undergo heavy and pre- B-cells light chain B-cell receptor 
(BCR) rearrangements. After functional rearrangement and BCR expression on the surface, 
the B cell is termed as mature or naïve and is released into the blood stream. Once 
encountering an antigen either in the blood or presented in lymph nodes by follicular dendritic 
cells (fDCs) where the mature/naïve B-cells pass by from time to time, there occurs together 
with T helper cells the formation of a follicle with germinal centres (GC). In the the GC 
reaction, B-cells with high affinity for a specific antigen are produced by somatic 
hypermutation. The activated and hypermutated B-cells can then either differentiate into 
antibody secernating plasma cells or enter the memory B-cell pool. 
A prominent viral gene hijacking B-cell differentiation pathways encodes for the latent 
membrane protein (LMP) 2A. LMP2A exploits the BCR signalling pathway generating a 
tonic signal which is needed for B-cell survival with crippled BCRs or for the initiation of the 
germinal centre (GC) reaction. Another prerequisite of LMP2A represents the regulation of 
latent and lytic EBV infection by blocking BCR signalling induced by binding of an antigen. 
These apparently opposite functions of LMP2A, on the one hand producing tonic BCR 
survival signals and on the other hand blocking BCR signal 1, 2, leads to the question how this 
dual function is achieved. Recent findings suggest specific functions of LMP2A depending on 
its protein levels present in the host cell. Furthermore, there is evidence that LMP2A levels 
are influenced and regulated by its isoform LMP2B which may influence the carefully 
maintained balance of host cell survival and lytic EBV infection described more in detail in 
section 2-5 3-5.
Another pathway in B-cell differentiation hijacked by EBV has recently been described. The 
cellular factor X-box binding protein (XBP)-1 was suggested as initiator of ultimately 
terminating latent EBV infection 6, 7. XBP-1 is active in plasma cells and increases the 
transcription of the master EBV lytic regulator gene BZLF1, which leads to the production of 
new infectious virions. This interesting finding links activation of lytic EBV directly to 
terminal B-cell differentiation into a plasma cell which is outlined in section 6.
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2. Epstein-Barr virus LMP2B: a rheostat for LMP2A signal strength
The LMP2 gene is transcribed into two mRNAs across the circularized EBV genome (i.e., 
across the terminal repeats) from two spatially distinct promoter elements. Both transcripts are 
multiply spliced and exons 2–9 are shared by both mRNAs. Exon 1 of LMP2A encodes a 
hydrophilic, N-terminal cytoplasmic domain of 119 amino acids, whereas exon 1 of LMP2B is 
non-coding, with translation beginning in the common exon 2 before the first transmembrane 
sequence 12-14. The remaining exons encode 12 transmembrane domains and a 27 aa, 
hydrophilic C terminus 12, 14. The molecular characteristics of LMP2A were recently reviewed 
by Brinkmann and Schulz 15. Since LMP2B is lacking the N-terminal domain, it has been 
postulated that interaction between LMP2A and LMP2B occurs via their C-termini 16. The 
expression of both isoforms together, LMP2A and LMP2B, was detected in HL and 
nasopharyngeal carcinoma (NPC) biopsies as well as in EBV-positive post-transplant-
lymphoproliferative diseases (PTLDs) and in in vitro transformed B-cells (lymphoblastoid 
cell lines (LCLs)) 17-21. The expression of LMP2A alone was detected only in peripheral blood 
memory B-cells 22 and in BL cells stimulated either by B-cell receptor (BCR) cross-linking or 
with chemical agents or biologicals including TPA, TGF-β, or 5-Azacytidine 23-29.
The regulation of LMP2A levels has been addressed in various publications and its need for 
differential expression levels seems to be evident for B-cells 30-35. Portis and co-workers 
suggested a regulation of LMP2A by ubiquitination 34. They proposed a model where 
ubiquitin protein ligase present in the cell is dependent on the levels of Notch. Notch is a 
transmembranal protein, which is cleaved upon binding to an extracellular ligand, releasing its 
intracellular part (NotchIC) for entering the nucleus 36-38. Once in the nucleus Notch activates 
RBP-Jk/CBF-1 which is involved in the regulation of many genes, among them genes 
important for lymphocyte development. As Notch and LMP2A are ubiquitinated by the same 
protein ligases, Portis and co-workers proposed that Notch sequesters the ligases in similar 
manner as LMP2A sequesters Scr kinases from the BCR complex 15 and thereby prevents 
ubiquitination dependent degradation of LMP2A. In other words, high protein levels of 
LMP2A result in ubiquitin-mediated degradation and the increase of Notch, and vice versa. 
This conclusion is supported by the fact that in HL, where LMP2A is expressed constitutively 
and sequesters ubiquitin ligases continuously, high Notch levels have been detected 39. 
Recently, it was shown that LMP2A influences Notch protein levels which in turn enhance 
transcription of LMP2A in B-cells and epithelial cells 40. Thus, LMP2A seems to control its 
expression levels via an auto-regulatory loop. However, through which pathway Notch is 
22
upregulated remains elusive. Taken together upregulation of LMP2A leads to a positive 
feedback loop on transcriptional and protein level.
Observations that LMP2B modulates the activity of LMP2A 5 and influences the induction of 
lytic EBV 3, 4 suggest that LMP2B is an important key player in regulating LMP2A’s 
degradation or LMP2A’s auto-regulatory loop. Thus, these findings prompted us to 
hypothesize that EBV modulates the protein levels of LMP2B to control the activity and/or 
protein levels of LMP2A and the strength of the BCR signal.
If the question is asked, whether LMP2B is a rheostat of LMP2A signal strength, an important 
prerequisite is, in which cellular compartment LMP2B interacts with and regulates the activity 
of LMP2A. There have been several reports on the localization of untagged and tagged 
LMP2B and LMP2A 3-5, 41-47 (Table 1). Both isoforms localize in different cellular 
compartments depending on the host cell. In B-cells with or without EBV, LMP2B shifted to 
intracellular compartments as perinuclear regions and the trans Golgi network (TGN) whereas 
LMP2A was found on the plasma membrane as well as in intracellular regions 3-5, 42-46 (Table 
1). In epithelial cells, including those in NPC biopsies, LMP2B and LMP2A were detected in 
the plasma membrane and intracellular regions 41, 43, 45-48 (Table 1). It has been shown that 
LMPB and LMP2A can interact physically and that the C-terminus shared by both isoforms 
contributes mainly for the clustering 4, 16. The protein domains which seem to be important for 
LMP2B localization and the ability to cluster with itself or heterodimerize with LMP2A were 
mapped to the transmembranal loops of LMP2B 47. 
LMP2B might regulate the activity of LMP2A in B-cells in different ways: as described in 
Figure 1, depending on the amount of newly translated LMP2A and LMP2B, the two 
isoforms may either homodimerize or heterodimerize in the TGN. The prevalence for 
dimerization lies in the expression levels of both proteins and is an important prerequisite for 
the regulation of BCR signalling.
When high amounts of LMP2A are translated, they homodimerize already in the TGN. 
However, as Syk, Lyn, and Nedd4 ubiquitin ligases are not or only in small amounts present 
in the TGN, LMP2A cannot sequester Scr kinases and ubiquitin ligases which would lead to 
ubiquitination and degradation of the participating proteins in proteasomes. Thus, vesicles 
containing LMP2A are able to traffic from the TGN to the plasma membrane where they fuse. 
After localizing to the plasma membrane, homodimerized LMP2A gets activated by 
phosphorylation. Upon activation, LMP2A assembles a signalosome in lipid rafts comprised 
of Scr kinases and ubiquitin ligases 49. This scenario is supported by the finding that 
constitutively expressed LMP2A is predominantly detected in lipid rafts on plasma 
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membranes 16, 50-52. However, recruitment of ubiquitin ligases leads to monoubiquitination of 
the members of the signalosome which in turn leads to internalization into endosomes 43, 53, 54. 
Depending on the state of ubiquitination, the fate of a protein is either to be reconstituted by a 
turn-over to the plasma membrane when monoubiquitinated or to be degraded in proteasomes
when polyubiquitinated 55.
As LMP2B is detected in intracellular compartments (Table 1) it might be possible that 
endocytosed signalosomes and vesicles containing LMP2B fuse. This would allow the 
disruption of the homodimerized LMP2A by LMP2B and the rescue of LMP2A and Scr 
kinases by deubiquinating enzymes (DUBs) 56 resulting in an intact turn-over process and 
proper BCR signal once triggered by a specific antigen. On the other hand, if there occurs no 
fusion with a LMP2B containing vesicle, the members of the endocytosed signalosome get 
degraded in proteasomes and BCR signalling cannot be realized.
As depicted in figure 1, shifting from high LMP2A levels to medium amounts of LMP2A and 
LMP2B in the B-cell, the isoforms can heterodimerize in the TGN and traffic in vesicles to 
the plasma membrane. Thus, Scr kinases and ubiquitin ligases do not assemble with LMP2A 
to a signalosome resulting in enough Syk and Lyn present in the system for proper BCR 
signalling once triggered by an antigen. This scenario is supported by the fact, that transient 
LMP2B expression in EBV negative BL BJAB cells overexpressing LMP2A restores Lyn 
levels and Ca2+ mobilization upon cross-linking which verified proper BCR signalling. 
Similarly, LMP2B abrogated the effect of LMP2A blocking BCR signalling in EBV-positive 
Akata cells overexpressing LMP2A 57.
Once the heterodimer consisting of LMP2A and LMP2B has fused with the plasma 
membrane, there can occur a reorganisation of dimers as the plasma membrane and its 
proteins is a dynamic layer where aggregation as well as separation of proteins happen 
continuously. Thus, disassembly and reassembly of heterodimers to homodimers might occur, 
leading either to LMP2A homodimers which in turn are endocytosed as described above, or to 
LMP2B homodimers. Whether LMP2B homodimerization in the plasma membrane has a 
physiological function in the B cell is highly hypothetical. Due to the fact that LMP2B dimers 
do not recruit Scr kinases and ubiquitin ligases, they do not get ubiquitinated and 
endocytosed. This would lead to an accumulation of LMP2B in the plasma membrane. 
However, as LMP2A levels may be upregulated, the excess of LMP2B could act as a buffer 
till a threshold concentration of LMP2A in the plasma membrane is reached and BCR 
signalling is blocked again.
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To complete the scenario described in Figure 1, the fate of high levels of LMP2B favouring 
homodimers in the TGN has to be addressed. In a recent publication, Tomaszewski-Flick and 
co-workers identified protein domains in LMP2B which, when deleted, allowed LMP2B to 
traffic to the plasma membrane 47. This implicates a retention domain in LMP2B. However, as 
LMP2A contains the same domains as LMP2B but is detected on the plasma membrane, the 
retention signal seems to be inactive or overridden, probably due to another dominant signal 
in the additional N-terminus. Whether LMP2B homodimers traffic from the TGN to the 
plasma membrane or LMP2B dimers can only be formed by reassembly as described above 
remains elusive and needs further investigations.
Table 1: Sub-cellular localization of LMP2 
Cell line Expression Sub-cellular localization Reference
BL Akata LMP2B Predominantly intracellular regions 4
BL Akata LMP2A Plasma membrane and intracellular regions 3, 4
BL BJAB LMP2A and LMP2B Plasma membrane and intracellular regions 5
BL BJAB LMP2A and ΔLMP2A Plasma membrane 44
BL BJAB LMP2A and LMP2B Perinuclear  intracellular regions / TGN 46
LCL LMP2A Perinuclear  intracellular regions / TGN 46
LCL LMP2A Plasma membrane 45
LCL LMP2A and ΔLMP2A Plasma membrane and intracellular regions 42
LCL LMP2A Plasma membrane and intracellular regions 43
HEK 293T LMP2A and LMP2B Perinuclear  intracellular regions / TGN 46
HEK 293T LMP2B Intracellular regions 47
HEK 293T Various ΔLMP2B Plasma membrane 47
BALB 3T3 LMP2A Plasma membrane and intracellular regions 45
A321, SCC12F, HaCat LMP2A and LMP2B Perinuclear vesicles 41
NPC biopsies LMP2A Plasma membrane and intracellular regions 48
LMP2A: Latent membrane protein 2A; LMP2B: Latent membrane protein 2B; BL: Burkitt’s lymphoma; LCL: lymphoblastoid cell line; Δ: 
deletion constructs; NPC: Nasopharyngeal carcinoma; TGN: trans-Golgi network
The proposed model of LMP2A and LMP2B in the different cellular compartments points out 
the importance of a very carefully regulated balance of the two isoforms. Increase of LMP2A 
or LMP2B protein levels shifts the balance either to a blocked or to an intact BCR signal upon 
antigen encounter, respectively. Due to the fact that only LMP2A can directly interfere with 
BCR signalling prompted us to propose LMP2B functioning as a rheostat for LMP2A signal 
strength. However, as the function of LMP2B in vivo is not yet revealed, we tried to integrate 
the proposed interaction between LMP2A and LMP2B depending on the stage of B-cell 
differentiation and nature of B-cell lymphoproliferative diseases into a model described in the 
following paragraphs and Figure 2.
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3. LMP2B and LMP2A: effects on B-cell differentiation at the germinal centre
There is a consensus in the scientific community that EBV targets epithelial cells and B cells 
in the oropharynx in primary infection 58. As it has been shown that EBV particles shed by 
epithelial cells infect B-cells to a higher rate and vice versa 59, 60, the first step of infection is 
production of a huge amount of virions. However, during productive replication, EBV 
expresses the whole repertoire of latent and lytic genes which leads to activation of the 
immune system 61. Whereas there is clearance of EBV positive epithelial cells by cytotoxic T-
cells 61, there occurs a shut down of the expression of EBV genes in B-cells, enabling the 
establishment of a latently infected memory B-cell pool 62.
Which B-cell subpopulations are infected by EBV has been an open field for discussion for 
many years. It has been long thought that only mature/naïve B-cells can be infected directly 
by EBV, first enhancing their proliferation and then differentiation leading through a ‘pseudo’ 
germinal centre (GC) reaction and getting access to the memory B-cell pool 21, 63. Recently, a 
model has been proposed in which the direct infection of GC B-cell is considered 64. This site 
of infection was then as well linked to the pathogenesis of  HL, where the RSCs show surface 
expression markers characteristic for GC B-cells 65. RSCs analysed so far showed crippled 
BCR rearrangement and the specific latency program II of EBV where LMP2A is expressed 
and is thought to deliver the tonic survival signal otherwise produced by the functional BCR 
66. However, we can only speculate about why the RSBs retain their GC B-cell characteristic 
and do not switch to memory B-cell phenotype. It might be that, although LMP1 is expressed 
and mimics the differentiation signal from CD40, the strength of the LMP2A signal is too low 
for an activated BCR in positive selection and therefore the GC B-cell is stock in its 
differentiation stage.
The possible role of LMP2B in GC B-cells directly infected by EBV might be that when 
positive selection with somatic hypermutation is induced by the binding of a foreign antigen 
to the BCR, the signal of LMP2A has to be regulated (Figure 2A). In the case of somatic 
hypermutation generating high affinity B-cells the presence of LMP2A would lead to a 
decrease of the signal due to less Scr kinases present in the lipid rafts, and possibly to 
induction of apoptosis. Thus, LMP2B might be expressed to downregulate the activity of 
LMP2A to allow the GC B-cell to enter the memory B-cell pool. On the other hand, when low 
affinity BCR rearrangements would lead to depletion of a B cell, the additional signal of 
LMP2A would enhance BCR signalling resulting in a high affinity signal and positive 
selection, as previously proposed 63, 67-69. Therefore, memory B-cells circulating in the 
periphery with low affinity to a foreign antigen are generated, in that way weakening the 
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adaptive immune response. However, whether a B-cell with low or high affinity for a foreign 
antigen is generated, there exists the possibility that during the GC reaction other 
translocations or mutations occur. Such genetic unfavourable hits include the translocation of 
c-myc and the malfunction of p53, both together leading to the phenotype of BL more closely 
described in section 5. 
A model where EBV directly infects memory B-cells has been proposed (Dorner et al. 
accepted for publication in JV) 70, 71. Tonsillar mature and memory B-cells are infected ex vivo
at similar frequencies. In contrast, memory B-cells from blood, which represent B-cells from 
various lymphoid tissues, are infected at lower frequencies than their mature counterparts. 
According to this model EBV exploits the B-cell differentiation status and tissue of origin to 
establish persistent infection. Whether EBV infects B cells in various differentiation status or 
mature naïve B-cells only as emphasized by Souza and co-workers 63, our model proposed in 
Figure 2 allows the integration of the regulatory function of LMP2B on LMP2A signal 
strength independently of the step of infection.
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4. LMP2B and LMP2A: effects on B-cell differentiation in the bone marrow
One major function of LMP2A is to deliver survival signals when EBV infects B-cells with 
non-functional heavy or light chain rearrangement 1, 67. This survival signal is generated by 
mimicking a tonic signal otherwise produced by the BCR using its cytosolic N-terminal 
domain recruiting the Scr kinases Syk and Lyn 2. The ability of EBV to enhance survival of 
death-doomed B cells and to access in that way the memory B-cell pool by the expression of 
LMP2A was underlined in in vivo models in RAG deficient 31 or ΔITAM-LMP2A transgenic 
mice 35. These experiments were done in mice with LMP2A integrated into the germline and 
show the rescue capability of LMP2A signalling in B-cells with non-functional BCRs. To 
translate this scenario into a human background, one has to assume that EBV infects pro- and 
pre- B-cells in the bone marrow. Indeed, there has been a publication detecting several EBV-
positive lymphoid cells on EBER-1 in situ hybridization (ISH) 72. However, as pro- and pre-
B-cells do not express CD21, the cellular surface receptor interacting with EBV’s gp350 
envelope protein, the attachment and entry of EBV into these cells remains elusive. In the 
following paragraphs we suggest a possible impact of LMP2A and LMP2B assumed that 
EBV infects the B-cells present in the human bone marrow. 
As in the bone marrow heavy and light BCR chains are rearranged, there is always a high 
amount of B-cells produced with non-functional BCRs. A possible outcome of B-cells with 
crippled BCR is the formation of HL where only a small subset of the tumour mass, the Reed-
Sternberg cells (RSCs), is accounted for the pathological situation 65, 73. It could be shown that 
the RSCs indeed have crippled BCRs and that LMP2A is expressed among other latent EBV 
genes defined as Latency II 66, 74-78. The RSCs resemble GC B-cells which suggests EBV 
infection of either mature B-cells, driving them into proliferation and differentiation to the GC 
reaction, or the direct infection of GC B-cells, rescuing malfunctional switch of heavy chain 
as well as low affinity or dysfunctional hypermutations of the variable regions 10. 
Additionally, this model allows the possibility of EBV infection of pro- and pre- B-cells with 
crippled BCRs which would be depleted by induction of apoptosis in the bone marrow.
As in the bone marrow not only B cells with crippled BCRs are depleted but also B-cells with 
BCRs binding to a self-antigen, this rises the question about what happens to pro- and pre B-
cells infected with EBV and a BCR-recognising self-antigen. In this scenario LMP2A would 
have to block the strong signal induced by the BCR/self-antigen complex. This leads to the 
hypothesis that LMP2A sequesters the Scr kinases Syk and Lyn and the Nedd4 ubiquitin 
protein ligases AIP4/Itchy, WWP2, Nedd4, and Nedd4-2/KIAA0439 53, 54. This constellation 
of the signalosome leads to ubiquitination and degradation of Lyn as was previously reported 
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32, 34, 53, 79. The situation in blocking the BCR signal due to low Lyn levels would be the same 
as observed in LCLs with high levels of endogenous LMP2A 79, BJAB BL cells 
overexpressing LMP2A 5, and BL Akata cells overexpressing LMP2A (unpublished results). 
The survival of B-cells recognizing self-antigen results in an increased memory B-cell pool of 
autoreactive B-cells of the subtype B1 33, 80. Generation of elevated numbers of autoreactive 
B-cells by EBV was discussed in the literature and is proposed to be linked with autoimmune 
diseases such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus 69, 
81-85.
With our hypothesis described in section 2 and Figure 1, it is as well possible to explain the 
survival of B-cells, from pro-B-cell state till mature B-cell, which have undergone functional 
BCR rearrangement, do not recognize self-antigen, and are infected with EBV. In these B-
cells, defined as subgroup B2 33, 80, the functional BCR provides the tonic survival signal 
already and LMP2A is not needed for any intervention or help. Thus, the ability of LMP2A to 
either provide at low levels a tonic signal or at high levels to block BCR signalling is 
abolished by the presence of LMP2B which disrupts homodimerization of LMP2A and its 
activity.
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5. LMP2B and LMP2A: effects on maintenance of latent EBV infection 
In order to exploit the memory B-cell pool in healthy individuals as the reservoir for latent 
EBV infection, there must be a tight control of viral gene expression and lytic EBV activation 
to avoid recognition by the immune system. The set of viral genes expressed in resting 
memory B-cells is restricted to the non-coding EBERs which cannot be sensed by the immune 
system and is defined as Latency 0 1, 10, 86. The stealth strategy of EBV allows the virus to 
survive without recognition by the innate or adaptive immune system and to establish latent 
infection in more than 90 % of the world population 87. However, the handicap of the stealth 
strategy is that EBV replicates only when its host-cell divide. The proper replication and 
segregation of the EBV genomes is warranted by the expression of EBNA1 which acts in cis
and is detected in dividing memory B-cells (Latency I) 10. Another viral gene detected in 
dividing memory B-cells, although very rarely, is LMP2A 22, 88. LMP2A blocks the signal 
after BCR cross-linking in in vitro transformed LCLs 89 and it is assumed that LMP2A exerts 
a similar function in vivo in memory B-cells that have encountered their specific antigen. This 
suggests a pivotal role of LMP2A in the maintenance of latent EBV infection.
This in vivo scenario is substantiated by an in vitro model using the EBV-positive BL cell line 
Akata 3, 4, 90. The advantage of the BL cell line Akata is, that it retains the EBV expression 
pattern found in biopsies when cultured (Latency I) whereas other BL cell lines switch with 
time to Latency III, characteristically expressing the EBV genes EBNA1-6, LMP1, LMP2A, 
and LMP2B 91. Apart from a c-myc translocation which is found in most BL cell lines 91, 
Akata cells exhibit a functional IgG rearrangement and hypermutation, therefore representing 
an optimal model to study EBV infected dividing memory B-cells 90. We and others have 
observed the upregulation of LMP2A 48-72 h after BCR cross-linking in Akata cells which 
might indicate an attempted rescue of latent infection 3, 92, 93. Thus, we investigated the impact 
of either silenced or overexpressed LMP2A or LMP2B on lytic EBV infection in Akata cells 
after BCR cross-linking 3, 4. This Akata model system revealed that lytic EBV infection either 
increased after BCR cross-linking compared to control cells when LMP2B was overexpressed 
or LMP2A was silenced, or conversely decreased when LMP2B was silenced or LMP2A was 
overexpressed. These findings underscored the function of LMP2A in vivo as described above 
and elucidated a potential function of its isoform LMP2B, namely to act as a rheostat for 
LMP2A signal strength.
Activated memory B-cells differentiate into antibody producing plasma cells 6. This 
differentiation step leads to the activation of lytic EBV infection with expression of lytic and 
latent viral genes, among them LMP2A 92, which triggers cytotoxic T-cell (CTL) response. 
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Recently published data report a decline in CTLs against immediate early viral antigenes but 
no decline specific for latent antigens 94. This observation might be limited because as read-
out of CTLs against latent antigenes only EBNA3C was measured. Therefore, whether 
LMP2A is expressed and triggers an CTL response which kills all activated EBV-positive B-
cells trying to escape terminal plasma cell differentiation as desribed below remains elusive. 
However, according to the model described in paragraph 2 and Figure 1, the upregulation of 
LMP2A leads to a depletion of Scr kinases and a block of BCR signal. As the activation and 
differentiation of memory B-cell takes several days in vivo 95-98, there might be enough time 
for EBV to act against plasma cell fate and disruption of EBV latency with the upregulation 
of LMP2A according to Figure 2B and the model described in Figure 1. If this occurs, these 
memory B-cells rescued from plasma cell differentiation, which as well have undergone 
clonal propagation, enter the memory B-cell pool again. Due to high rates of division in clonal 
propagation and because EBV seems to increase genomic instability 91, there might be, 
although very rarely but more frequently than without EBV, c-myc translocations which lead 
to uncontrolled growth and tumour formation characteristic for BL. Moreover, a recent 
publication describes activated memory B-cells in GC reactions which undergo a second 
clonal propagation and somatic hypermutation for even higher affinity, which further 
increases the probability of accumulating transforming genetic hits 99. To assign possible 
functions of LMP2B depending on B-cell differentiation stage in our model, we hypothesize 
that expression of LMP2B in activated memory B-cells might lead to decreased LMP2A 
activity and increased Scr levels (Figure 2B). The restoration of proper BCR signalling forces 
the activated memory B-cell towards a plasma cell phenotype and disrupts latent EBV 
infection.
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6. XBP-1: cellular sensor for latent EBV disruption 
Recent publications identified the host cell gene X-box binding protein (XBP)-1 as a factor 
responsible for the termination of latent EBV infection 6, 7. XBP-1 is a leucin zipper 
transcriptional activator protein, which is upregulated in the early processes of terminal 
plasma cell differentiation. It belongs to the CREB/ATF family and upregulates the 
transcription of the master EBV lytic regulator gene BZLF1. Whether XBP-1 interacts directly 
with the promoter region of BZLF1 or exploits an indirect pathway remains controversial 6, 7. 
Importantly, Bhende et al. 7 and Sun et al. 6 reported lytic EBV infection upon XBP-1 
activation. These findings are supported by the identification of lytic EBV infection in plasma 
cells of tonsillar B-cells in vivo 97, 100 and in tonsillar B-cells infected with EBV ex vivo
undergoing terminal differentiation (Dorner et al., accepted for publication in JVI). 
Furthermore, it was shown that Kaposi’s sarcoma-associated herpesviruses (KSHV) are 
activated by XBP-1 or that human CMV 101 and HTLV-1 102 use XBP-1 in their life cycle.
Thus, EBV terminates its latent infection by hijacking the XBP-1 pathway. This enables the 
virus not only to use the enhanced transcription and translation machinery from the 
differentiating plasma cell but serves as well as back door for the virus to escape the host cell 
doomed to death due to terminal differentiation. On the other hand, as EBV is found 
preferentially in vivo in its latent form, the virus might have evolved effective mechanisms to 
regulate or even suppress its activation. Therefore, the upregulation of viral genes hijacking 
and blocking the terminal plasma cell differentiation process would allow the maintenance of 
persistence. As the physiological plasma cell differentiation, which includes the upregulation 
of plasma cell-specific transcription factors like BLIMP-1, XBP-1, and the unfolded protein 
response (UPR) 95-98, takes several days, there might be enough time for this intervention. 
Such a viral gene interfering with the plasma cell differentiation inducing signal is, as 
described above, LMLP2A.
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Concluding remarks
In summary, recent publications hint to the existence of viral and cellular sensors in the 
regulation of latent and lytic EBV infection. LMP2B seems to regulate the dual function of 
LMP2A comprised of BCR block and survival signal. These findings suggest a function of 
LMP2B acting as a rheostat of LMP2A signal strength in B cells. The fact that LMP2B is 
conserved in EBV over the evolution and shares sequence homologies even with the rhesus 
monkey lymphocryptovirus (LCV) infecting Old World primates 103, indicate a strong 
selective pressure and an important function of LMP2B in the regulation of latent and lytic 
EBV infection. On the other hand, XBP-1 seems to be involved directly in the termination of 
latent EBV infection and links it to plasma cell differentiation. To amalgate the roles of 
LMP2B and XBP-1 in terminating latent EBV infection, will be an issue of future research. It 
might be that LMP2B acts on transcriptional and/or translational level on XBP-1 and vice 
versa. Additionally, there might as well be factors which drive the expression of LMP2B or 
stabilize the protein. However, which cellular factors these are and if they are dependent only 
on the plasma cell differentiation stage or on other factors as well, like senescence or stress, 
remains elusive and needs further investigations.
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Figure legends
Figure1: Possible pathways how LMP2B might act as a rheostat for LMP2A and BCR 
signalling. Left side panel: Newly translated LMP2A dimerize in the TGN or in vesicles on 
the way to the plasma membrane. As there are no or only small amounts of Scr kinases and 
ubiquitin ligases present, LMP2A is able to reach the plasma membrane. Once arrived at the 
plasma membrane, LMP2A dimers are organized in a signalosome consisting of Scr kinases 
and ubiquitin ligases, leading to ubiquitination and internalization. Further polyubiquitination 
leads to degradation in proteasomes which results in a block of BCR signal once a specific 
antigen is encountered due to depletion of signalling proteins. Another possible pathway 
might exist in the fusion of the endocytosed signalosome with a LMP2B containing vesicle. 
LMP2B is able to disrupt LMP2A homodimers which induces deubiquitination by 
deubiquitinating enzymes (DUBs). Deubiquitination allows a turn-over of internalized 
proteins back to the cell surface and restores proper BCR signalling. Middle panel: LMP2B 
and LMP2A heterodimers segregate to the plasma membrane. As there is no activation of 
LMP2A, enough Scr kinases are present in the case of a BCR signal induced from an antigen. 
At the plasma membrane there might occur disassembly and reassembly of either LMP2A 
(described above) or LMP2B (described below) homodimers depending on the expression 
levels of both proteins. Right side panel: LMP2B homodimers on the plasma membrane 
would allow an intact BCR signal upon antigen encounter.
Figure2: Effects of LMP2B and LMP2A on B-cell differentiation. (A) Germinal centre:
Non-functional class switch or hypermutation normally leads to cell death. EBV rescues these 
B cells by the expression of LMP2A. These surviving B cells might give rise to the formation 
of HL. Hypermutation generates (i) low and (ii) high affinity B cells for foreign antigens. (i) 
LMP2A and low BCR signal together might result in strong enough signal for proper 
germinal centre (GC) reaction and differentiation into a memory B-cell. (ii) LMP2B might 
abolish the activity of LMP2A, thus enabling proper BCR signal. The GC reaction favours, 
among others, c-myc translocation and p53 malfunction, increasing the possibility of Burkitt’s 
lymphoma (BL) formation. (B) Blood and secondary lymphoid tissue: Upon foreign antigen 
encounter, a specific memory B-cell is activated and starts with clonal expansion. A part of 
the cells expands for the maintenance of the memory B-cell pool. Another part starts to 
differentiate into plasma cells. As EBV tries to maintain latency, it upregulates LMP2A, in 
that way blocking BCR signalling and lytic EBV activation. Increased division in clonal 
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propagation favours c-myc translocation and p53 malfunction which may lead to the 
formation of BL. LMP2B might be stabilized by yet unknown factors in the cells (i.e. plasma 
cell factors, senescence, stress). LMP2B disrupts the ability of LMP2A to block BCR 
signalling and forces the memory B-cell towards plasma cell fate. XBP-1 is upregulated in 
terminal plasma cell differentiation and triggers lytic EBV.
: LMP2A : LMP2B : B-cell receptor (BCR) : BCR signal X : BCR signal blocked
Figure 1: Possible pathways how LMP2B might act as a rheostat for LMP2A and BCR signalling
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5. Subject of investigation
Due to the fact, that EBV-associated malignancies are treated nowadays with radio- and 
chemotherapy with still not satisfactory cure rates including severe side effects and due to the 
fact, that these tumors contain EBV in up to 100% of the tumor mass, gave rise to the 
formulation of a new tumor therapy: induction of lytic EBV infection leading to destruction of 
EBV-harboring tumor cells. Although EBV has been known for several decades, there are still 
many unknowns in the equation of how the virus regulates its latent and lytic form. Thus, the 
aim of this thesis was to determine factors destabilizing latent EBV infection. As a promising 
target, we selected the latent membrane protein (LMP)2B, about which we got evidence in 
preliminary studies to increase lytic EBV infection upon activation of the virus harboring B-
cell. To elucidate the mechanism how LMP2B may be involved in the regulation of lytic EBV 
infection, we approached the question on the one hand by silencing LMP2B and on the other 
hand by overexpression. As a system to study the impact of silencing and overexpression of 
LMP2B we chose the EBV positive BL cell line Akata in which lytic EBV infection can be 
triggered using BCR cross-linking.
Our concept of exploiting switching from latent EBV infection to lytic infection could as well 
serve as a model to fight other herpes viral-induced cancers. Finally, this project could also 
lead to new insights assisting the improvement of silencing or overexpression of genes from 
other viruses contributing to cancer development as , e.g., HCV or, more generally, of human 
oncogenes. The ultimate goal is the translation of these experimental efforts to the bedside, 
for treatment of patients affected by malignancies associated with EBV.
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6. Results
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therapies. The DNMTI 5-Azacytidine is effective against myelodysplastic syndrome, but 
induces switching of latent to lytic Epstein-Barr virus (EBV) in vitro and results in EBV DNA 
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induce expression of E-cadherin, a cellular gene frequently silenced by hypermethylation in 
cancers, and thus demonstrate that both DNMTI are active in our experimental setting 
consisting of EBV-harboring Burkitt's lymphoma Akata cells. Quantification of mRNA 
expression of EBV genes revealed that 5-Azacytidine induces switching from latent to lytic 
EBV and, in addition, that the immediate-early lytic infection progresses to early and late lytic 
infection. Furthermore, 5-Azacytidine induced upregulation of the latent EBV genes LMP2A, 
LMP2B, and EBNA2 in a similar fashion as observed following switching of latent to lytic 
EBV upon cross-linking of the B-cell receptor. In striking contrast, Zebularine did not exhibit 
any effect neither on lytic nor on latent EBV gene expression. Thus, Zebularine might be safer 
than 5-Azacytidine for the treatment of cancers in EBV carriers and could also be applied 
against EBV-harboring tumors, since it does not induce switching from latent to lytic EBV 
which may result in secondary EBV-associated malignancies.
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Abstract
Epigenetic silencing of regulatory genes by aberrant methylation contributes to tumorigenesis.
DNA methyltransferase inhibitors (DNMTI) represent promising new drugs for anti-cancer
therapies. The DNMTI 5-Azacytidine is effective against myelodysplastic syndrome, but induces
switching of latent to lytic Epstein-Barr virus (EBV) in vitro and results in EBV DNA demethylation
with the potential of induction of lytic EBV in vivo. This is of considerable concern given that
recurrent lytic EBV has been linked with an increased incidence of EBV-associated lymphomas.
Based on the distinct properties of action we hypothesized that the newer DNMTI Zebularine
might differ from 5-Azacytidine in its potential to induce switching from latent to lytic EBV. Here
we show that both 5-Azacytidine and Zebularine are able to induce expression of E-cadherin, a
cellular gene frequently silenced by hypermethylation in cancers, and thus demonstrate that both
DNMTI are active in our experimental setting consisting of EBV-harboring Burkitt's lymphoma
Akata cells. Quantification of mRNA expression of EBV genes revealed that 5-Azacytidine induces
switching from latent to lytic EBV and, in addition, that the immediate-early lytic infection
progresses to early and late lytic infection. Furthermore, 5-Azacytidine induced upregulation of the
latent EBV genes LMP2A, LMP2B, and EBNA2 in a similar fashion as observed following switching of
latent to lytic EBV upon cross-linking of the B-cell receptor. In striking contrast, Zebularine did not
exhibit any effect neither on lytic nor on latent EBV gene expression. Thus, Zebularine might be
safer than 5-Azacytidine for the treatment of cancers in EBV carriers and could also be applied
against EBV-harboring tumors, since it does not induce switching from latent to lytic EBV which
may result in secondary EBV-associated malignancies.
Findings
Abnormal hypermethylation of the promoters of cancer-
related or tumor suppressor genes is commonly found in
primary neoplasms and tumor cell lines [1]. Thus, phar-
macologic inhibition of DNA methylation could provide
an effective means of epigenetic anti-cancer treatment.
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dine and DNA methylase inhibitor (DNMTI), has proven
to be effective against myelodysplastic syndrome in a
phase III randomized clinical trial [2]. 5-Azacytidine
forms covalent complexes with cytosine- [C5]-specific
DNA methyltransferases and inhibits their activity [3]. In
addition, 5-Azacytidine is activated by uridine-cytidine
kinase and can be incorporated into both RNA and DNA.
Incorporation into RNA interferes with protein transla-
tion [4], which is the cause of 5-Azacytidine toxicity. This
substance is also characterized by a low stability in aque-
ous solution [5,6].
Different types of cancers including Burkitt's lymphoma
(BL) and nasopharyngeal carcinoma (NPC) harbor latent
Epstein Barr virus (EBV) [7] and maintenance of latent
EBV is partially mediated by hypermethylation of the EBV
genome. Thus, it is not surprising that 5-Azacytidine
induces switching of latent to lytic EBV in vitro [8-11] and
results in EBV DNA demethylation in NPC patients with
the potential of induction of lytic EBV [12]. Recurrent lytic
EBV caused by chronic disruption of EBV latency due to
long-lasting methotrexate treatment in EBV-carrying rheu-
matoid arthritis and polymyositis patients has been
linked with an increased incidence of EBV-associated lym-
phomas [13]. Therefore, since DNMTI need to be admin-
istered for long periods of time to treat cancers, DNMTI
with the potential to induce lytic EBV could have detri-
mental consequences in EBV carriers and be inappropriate
to combat EBV-carrying tumors.
Zebularine (1-(β-D-ribofuranosyl)-1,2-dihydropyrimi-
din-2-one), a newer cytidine analog containing a 2-(1H)-
pyrimidinone ring, acts as 5-Azacytidine by forming cova-
lent complexes with DNMT [14], and in addition acts as
transition state analog inhibitor of cytidine deaminase by
binding covalently at the active site [15]. In comparison to
5-Azacytidine, Zebularine has little toxicity; shows
increased stability [16,17], and targets preferentially
tumor cells [18]. Hence, Zebularine promises to be a bet-
ter drug than 5-Azacytidine for epigenetic therapy of can-
cer. Nevertheless, the potential of Zebularine in inducing
lytic EBV is unknown.
Based on the distinct properties we hypothesized that
Zebularine might differ from 5-Azacytidine in its potential
to induce lytic EBV. Thus, we compared the effects of both
DNMTI on EBV latency in the BL cell line Akata, a well-
established model to study switching of latent to lytic EBV
which also allows the study of DNMTI effects on cellular
genes silenced in cancer cells.
We first determined the concentrations of 5-Azacytidine
and Zebularine without cytotoxicity within 48 h. The
highest sub-toxic concentration of 5-Azacytidine was 1
μM (Fig. 1a) and of Zebularine was between 0.03 mM and
0.1 mM (Fig. 1b).
To validate our experimental conditions we next meas-
ured in Akata cells the expression of cellular genes known
to be reactivated by Zebularine in other tumor cell lines
including CDKN1A, CDKN1B and CDKN2A genes
[18,19]. Using quantitative real-time PCR (qRT-PCR),
expression of these cyclin-dependent kinases (CDK) was
already detectable in the non-treated cells and did not fur-
ther increase upon treatment neither with 5-Azacytidine
nor Zebularine (not shown) suggesting that in the p53
mutated Akata cells [20] these CDKs are not silenced by
hypermethylation. This did not hold true for E-cadherin
(CDH1). E-cadherin mediates cell adhesion and loss of its
expression by hypermethylation [21] is responsible for
increased cancer invasiveness and metastasis [22]. CDH1
expression is reactivated by 5-aza-2'-deoxycytidine treat-
ment in the BL cell line Raji [23]. We therefore measured
the expression of CDH1 by qRT-PCR in treated Akata cells
(Fig. 1c and 1d). Expression of CDH1 was not detectable
in non-treated Akata cells. Treatment with 1.0 μM 5-Aza-
cytidine resulted in a 30-fold induction of CDH1 mRNA
expression after 48 h, that increased to 150-fold at 72 h.
At a concentration of 0.5 μM, 5-Azacytidine showed a
maximal 30-fold activation of CDH1 after 72 h and at 0.1
μM had no significant effect on expression of CDH1
mRNA even after 72 h. Zebularine (100 μM) induced a
50-fold activation of CDH1 after 120 h (5 days), that was
sustained and increased to 100-fold after 10 days of con-
tinuous Zebularine treatment. This delayed effect was
expected since Zebularine follows a slower kinetic with
maximal effects later than 5-Azacytidine also in other cel-
lular backgrounds [18,24]. These results show that 5-Aza-
cytidine and Zebularine are able to induce expression of
CDH1 known to be frequently silenced by hypermethyla-
tion [22,25], and demonstrate that both DNMTI are active
in our experimental setting.
The first step in activation of lytic EBV infection is the
expression of the immediate-early lytic EBV gene BZLF1.
Zta, the product of BZLF1, is a transcription factor that
regulates the expression of early lytic EBV genes, and acti-
vates the lytic EBV gene expression program [26]. To deter-
mine the effects of 5-Azacytidine and Zebularine on
switching latent to lytic EBV in Akata cells, we measured
the mRNA expression of BZLF1 by qRT-PCR in Akata cells
treated with increasing concentrations of 5-Azacytidine at
48 h and 72 h and for Zebularine at up to 10 days. 1 μM
5-Azacytidine was able to induce activation of BZLF1
mRNA expression (Fig 1e). Induction of BZLF1 mRNA
was robust, reaching about 280-fold over mock-treated
cells. 5-Azacytidine concentrations lower than 1 μM did
not have a significant effect on BZLF1 mRNA expression.
Cytotoxic concentrations higher than 1 μM also activatedPage 2 of 6
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Response of Burkitt's lymphoma Akata cells to 5-Azacytidine and Zebularine treatmentFigure 1
Response of Burkitt's lymphoma Akata cells to 5-Azacytidine and Zebularine treatment. (a, b) Determination 
of non-toxic concentrations for Akata treatment in vitro with 5-Azacytidine (a) and Zebularine (b). 5 × 105 viable cells 
were seeded in 1 ml medium with increasing 5-Azacytidine or Zebularine concentrations. Living cells (trypan-blue exclusion) 
were then counted after 48 h and 72 h. The highest non-toxic-concentrations are: 1 μM 5-Azacytidine (a) and 100 μM for 
Zebularine (b). (c, d) Expression of E-cadherin (CDH1) normalized to HMBS. Treatment with 1.0 μM 5-Azacytidine 
resulted in a 30-fold induction of CDH1 expression after 48 h (c), and with slower kinetics 100 μM Zebularine induced a 60-
fold activation after 120 h and was sustained after 8 days of continuous Zebularine treatment (d). (e, f) BZLF1 expression 
indicating initiation of lytic EBV was observed after 1 μM 5-Azacytidine treatment (e), while 30 μM or 100 μM Zebularine do 
not activate BZLF1 expression, even after 8 days (f). Data in a-f are given as means ± SD from three independent experiments 
(g, h) Expression of early and late lytic EBV genes. Treatment with 5-Azacytidine results in increased expression of both 
EBV early and late antigens (g). Treatment with Zebularine did not show any significant increase of expression of early or late 
lytic antigens (h). (i, j) Expression of latent EBV genes LMP2A and EBNA2 increased around 10-fold upon treatment with 
1.0 μM 5-Azacytidine. EBNA2 expression increased about 60-fold by 0.5 μM and 1.0 μM 5-Azacytidine at 48 h. The lowest 5-
Azacytidine concentration used (0.1 μM) was also able to induce a 50-fold increase of EBNA2 expression at 72 h (i). LMP2B did 
show a maximal increase when treated with 1 μM 5-Azacytidine. (i). Treatment with Zebularine concentrations between 0.03 
mM and 1 mM did not have a significant effect on LMP2B and EBNA2 gene expression up to 72 h (j). Data in g-j are given as 
means of three independent experiments.
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shown). Treatment of Akata cells with 100 μM Zebularine
did not result in induction of BZLF1 mRNA (Fig. 1f).
Higher concentrations of Zebularine in the range of 1 mM
to 3 mM resulted in a 10-fold induction of BZLF1 mRNA
(not shown), likely due to stress response to cytotoxic
insult, rather than specific activation of BZLF1 mRNA
expression. These results confirm that 5-Azacytidine initi-
ates lytic EBV infection at sub-toxic concentrations and in
addition demonstrate that by contrast treatment with
Zebularine up to 10 days does not provoke any change in
BZLF1 mRNA expression levels in Akata cells.
To elucidate whether activation of the master regulatory
lytic EBV gene BZLF1 by 5-Azacytidine is followed by acti-
vation of early and late lytic EBV genes and whether Zebu-
larine does activate other lytic EBV genes independently of
BZLF1 we also quantified mRNA expression of BALF1,
BMRF1, and BXLF2 (Fig. 1g and 1h). BALF1 codes for an
anti-apoptotic cytoplasmic early lytic antigen, BMRF1 for
the early antigen-diffuse EA-D, and BXLF2 for the late lytic
antigen glycoprotein gp85. Treatment of Akata cells with
1 μM 5-Azacytidine resulted in increased expression of
both early and the late lytic antigens at 48 h with surpris-
ingly similar kinetics. Even 0.1 μM 5-Azacytidine was able
to increase mRNA expression of lytic EBV genes by a ten-
fold at 72 h. By contrast, no expression of early or late lytic
EBV genes was measurable in Akata cells treated with
Zebularine. Even treatment with 1 mM Zebularine; a con-
centration that apparently did induce expression of BZLF1
mRNA after 48 h, was not able to activate mRNA expres-
sion of other lytic EBV genes. This supports our above
mentioned interpretation that expression of BZLF1
mRNA at a 1 mM Zebularine dose was not a specific event
with subsequent full lytic EBV gene expression. These
results indicate that 5-Azacytidine activates all three
phases of lytic EBV infection and evidence that Zebularine
does not induce switching from latent to lytic EBV.
The failure of Zebularine to induce switching from latent
to lytic EBV could be due to either having no effect on EBV
at all or due to reinforcement of latent EBV gene expres-
sion. Thus, we compared the quantitative mRNA expres-
sion of latent EBV genes before and during treatment with
5-Azacytidine or Zebularine. Treatment of Akata cells with
1.0 μM and 0.5 μM 5-Azacytidine increased LMP2A
mRNA expression by 10-fold at 48 h and at 72 h, respec-
tively, and LMP2B mRNA by around 10-fold at 48 h (1.0
μM). The effects on EBNA2 mRNA expression were more
marked with an increase by 60-fold using 5-Azacytidine at
0.5 μM and by 400-fold at 1.0 μM at 48 h. Even the lowest
5-Azacytidine concentration used (0.1 μM) was able to
induce a 30-fold increase of EBNA2 mRNA expression at
72 h (Fig. 1i). We and others have previously shown a
similar activation of LMP2 and EBNA2 upon induction of
lytic EBV by IgG cross-linking in Akata cells [27,28]. In
striking contrast, none of the tested Zebularine concentra-
tions exhibited an effect on latent EBV gene expression
(Fig. 1j), suggesting that the failure of Zebularine to
induce switching of latent to lytic EBV is not due to rein-
forcement of latent EBV gene expression. We therefore
conclude that Zebularine has no effect on EBV gene
expression in Akata cells, neither on lytic nor latent.
In the BL cell line Akata, both 5-Azacytidine and Zebular-
ine are able to reactivate an important regulatory gene like
E-cadherin, which when silenced by hypermethylation
contributes to cell malignancy. Hypermethylation is also
an important regulatory mechanism of EBV latency. This
is emphasized by the fact that EBV can modulate the activ-
ity of DNA methyltransferases through the latent mem-
brane protein LMP1, that can induce activation of DNA
methyltransferases in epithelial carcinoma and lead to
silencing of E-cadherin expression [29]. 5-Azacytidine and
Zebularine act by different mechanisms [24]. Impor-
tantly, here we show that Zebularine, unlike 5-Azacyti-
dine, does not disrupt EBV latency. Thus, Zebularine
might be safer than 5-Azacytidine for the epigenetic treat-
ment of cancers in EBV carriers and could also be
employed to treat EBV-harboring tumors, since it does not
induce switching from latent to lytic EBV a process linked
to secondary EBV-associated malignancies.
Materials and methods
Cell lines
The human BL cell line Akata was cultured in RPMI 1640
medium (Invitrogen, Basel, Switzerland), supplemented
with 10% heat-inactivated fetal calf serum, L-Glutamine
(1%), penicillin (1 U/ml), streptomycin (1 μg/ml). The
human bladder carcinoma cell line T24 was cultured in
McCoy's medium supplemented with 10% fetal calf
serum, L-Glutamine (1%), penicillin (1 U/ml), strepto-
mycin (1 μg/ml). The cells were grown at 37°C in 5% CO2
humidified atmosphere and split every third day. Akata
cell line was a kind gift from Dr. A. Bell (Birmingham,
UK), and T24 cell line was a kind gift from Dr. H.
Wunderli-Allenspach (ETH Zürich, Switzerland). The
optimal cell density (5 × 105 cells/ml) for experiments
with Akata cells allowed logarithmic cell growth over the
observation period.
DNA-methylase inhibitor treatments
5-Azacytidine was purchased from Sigma-Aldrich Chemie
Gmbh (Buchs, Switzerland) as lyophilized powder and
stored at -20°C. 5-Azacytidine solution was prepared
fresh for each experiment in PBS at a concentration of 2.4
mg/ml (10 mM) and sterile filtered. Zebularine was pur-
chased from Calbiochem (Merk Biosciences, Darmstadt,
Germany) and stored at 4°C. Zebularine was dissolved in
PBS at a concentration 28.5 mg/ml (120 mM), sterile fil-Page 4 of 6
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cells, viable cells were counted by trypan-blue exclusion
method and resuspended in fresh medium at 0.5 × 106
cells/ml. T24 cell line experiments were performed as
described [18].
Quantitative real-time PCR analysis
RNA isolation was then performed by using Rneasy Mini
Kit (Qiagen, Hombrechtikon, Switzerland) according to
the manufacturer's protocol. Contaminating genomic
DNA was removed by using DNA-free (Ambion Europe,
Huntingdon, UK) according to the manufacturer's proto-
col. The RNA concentration was measured with an Eppen-
dorf Bio Photometer (Vaudaux Eppendorf, Dübendorf,
Switzerland). cDNA was prepared by reverse transcription
of total RNA using the Omniscript RT-Kit (Quiagen) fol-
lowing the manufacturer's protocol. qRT-PCR was per-
formed in a reaction volume of 10 μl with the ABI-
TaqMan Master Mix with uracil-N-glycosylase (Applied
Biosystems, Rotkreuz, Switzerland). Sequence informa-
tion for the Taqman systems will be furnished upon
request. mRNA expression of the target genes was normal-
ized to the expression of the housekeeping gene HMBS
[30]. The normalized transcription values correspond to
2-CT(EBV)-CT(HMBS) = 2-ΔCT, where CT is the cycle threshold
number that quantifies the target present.
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6.2 Silencing of latent membrane protein 2B (LMP2B) reduces susceptibility to activation 
of lytic Epstein-Barr virus in Burkitt’s lymphoma Akata cells.
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Abstract
Epstein–Barr virus (EBV) latent membrane protein2A (LMP2A) blocks B-cell receptor 
(BCR) signalling after BCR cross-linking to inhibit activation of lytic EBV, and ectopically 
expressed LMP2B negatively regulates LMP2A. Here, it is demonstrated that silencing of
LMP2B in EBV-harbouring Burkitt’s lymphoma Akata cells results in reduced expression of
EBV immediate – early lytic BZLF1 gene mRNA and late lytic gp350/220 protein upon BCR
cross-linking. Similarly, reduction of lytic EBV activation was observed in Akata cells
overexpressing LMP2A. In contrast, silencing of LMP2A expression resulted in higher lytic
EBV mRNA and protein expression in BCR cross-linked Akata cells. These observations
indicate a role for LMP2B distinct from that of LMP2A in regulation of lytic EBV activation
in the host cell and support the hypothesis that LMP2B exhibits a negative-regulatory effect
on the ability of LMP2A to maintain EBV latency by preventing the switch to lytic
replication.
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Epstein–Barr virus (EBV) latent membrane protein 2A (LMP2A) blocks B-cell receptor (BCR)
signalling after BCR cross-linking to inhibit activation of lytic EBV, and ectopically expressed
LMP2B negatively regulates LMP2A. Here, it is demonstrated that silencing of LMP2B in
EBV-harbouring Burkitt’s lymphoma Akata cells results in reduced expression of EBV immediate-
early lytic BZLF1 gene mRNA and late lytic gp350/220 protein upon BCR cross-linking.
Similarly, reduction of lytic EBV activation was observed in Akata cells overexpressing LMP2A.
In contrast, silencing of LMP2A expression resulted in higher lytic EBV mRNA and protein
expression in BCR cross-linked Akata cells. These observations indicate a role for LMP2B
distinct from that of LMP2A in regulation of lytic EBV activation in the host cell and support
the hypothesis that LMP2B exhibits a negative-regulatory effect on the ability of LMP2A to
maintain EBV latency by preventing the switch to lytic replication.
Epstein–Barr virus (EBV) is a human B-lymphotropic
c-herpesvirus that, following primary infection, persists
latently in the host’s memory B-cell pool for life and may
switch periodically to lytic infection (Rickinson & Kieff,
2001). EBV is linked with malignancies including Burkitt’s
lymphoma (BL), Hodgkin’s lymphoma, nasopharyngeal
carcinoma and post-transplant lymphoproliferative dis-
eases (Murray & Young, 2002), where it expresses different
patterns of latency genes (Fruehling & Longnecker, 1997;
Rowe, 1999). Latent EBV transforms B cells in vitro (Young
& Murray, 2003). The two latent membrane proteins,
LMP2A and LMP2B, are dispensable for this transforma-
tion (Longnecker et al., 1992; Speck et al., 1999), but seem
to be involved in the maintenance of EBV latency.
Transcription of LMP2A and LMP2B is controlled by two
promoters separated in the DNA by 3 kb (Sample et al.,
1989). The two mRNAs encoding the proteins LMP2A and
LMP2B have different 59 exons followed by eight common
exons. LMP2A contains an N-terminal cytoplasmic domain
of 119 aa, with eight tyrosines that are phosphorylated in
lymphoblastoid cell lines, 12 transmembrane domains and
a C-terminal domain of 12 aa. LMP2B differs from LMP2A
by the lack of the entire N-terminal cytoplasmic domain,
which promotes B-cell survival by blocking B-cell receptor
(BCR) signalling transduction through several signalling
pathways (Fruehling et al., 1996; Fruehling & Longnecker,
1997; Longnecker et al., 1991; Miller et al., 1994b; Swart
et al., 2000). Cross-linking of BCR on EBV-infected cells
induces lytic EBV replication through transcriptional
activation of the EBV immediate-early lytic gene BZLF1.
In lymphoblastoid cell lines, LMP2A interferes with this
process by blocking the activation of protein tyrosine
kinases (Miller et al., 1994a, 1995). This mechanism is
thought to prevent lytic EBV replication in latently infected
B cells circulating in the body upon encounter of antigens
or other ligands that may engage BCR (Portis et al., 2002).
Indeed, LMP2A expression is found in EBV-infected
tonsillar memory B cells ex vivo (Babcock & Thorley-
Lawson, 2000; Babcock et al., 2000). Furthermore, B cells in
LMP2A-transgenic mice show increased survival (Caldwell
et al., 2000; Merchant et al., 2000). These observations
suggest a central role for LMP2A to ensure persistence of
EBV latency within the infected cell.
LMP2B, as for LMP2A, has been shown to promote spread
and motility of epithelial cells (Allen et al., 2005), but little
is known about the function of LMP2B in B cells. LMP2B
co-localizes with LMP2A in the membrane, where the C
termini of both splice variants can interact and regulate the
activity of each other (Lynch et al., 2002; Matskova et al.,
2001). Recently, LMP2B was shown to regulate LMP2A
activity negatively when these genes were expressed in the
EBV-negative BL cell line BJAB (Rovedo & Longnecker,
2007). Nevertheless, the role of LMP2B in the presence of
EBV remains unknown.3These authors contributed equally to this work.
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We hypothesized that LMP2B exhibits a role distinct from
that of LMP2A in activation of EBV lytic replication. To
test our hypothesis, we compared the impact of LMP2B
silencing with the impacts of LMP2A overexpression and
LMP2A silencing on activation of EBV lytic replication in
the EBV-harbouring BL cell line Akata upon BCR cross-
linking (Takada, 1984). Akata cells retain an EBV gene
expression pattern in vitro that closely resembles that found
in BL biopsies, and are an established model for the study
of activation of EBV lytic replication, which can be
triggered effectively by BCR stimulation using cross-linking
anti-IgG (Daibata et al., 1990).
To silence expression of LMP2B specifically, we con-
structed a short hairpin (sh) RNA targeting exon 1 of
LMP2B. The shRNA was designed by using the software
RNAi Central (http://katahdin.cshl.org) and is available
upon request. We cloned the shRNA into the lentiviral
vector pSICOR (Ventura et al., 2004), verified it by
sequencing and named the construct pSICOR-LMP2B-68
(Table 1). After LMP2B-68 shRNA lentiviral production in
HEK 293T cells (Graham et al., 1977), we incubated wild-
type Akata (Akatawt) cells with concentrated virus-contain-
ing supernatant and amplified them for 1 month in culture
using medium supplemented with G418 (0.4 mg ml21).
To monitor uptake of pSICOR-LMP2B-68, we tested
transduced Akata cells for expression of enhanced green
fluorescence protein (EGFP) by flow cytometry. To obtain a
homogeneous EGFP-expressing cell population (99% pur-
ity), we enriched EGFP-expressing cells by fluorescence-
activated cell sorting (FACS) twice and selected only for
cells with high EGFP expression levels (Table 1). We
independently transduced and selected three cell popula-
tions as described above to be used as biological replicates
and designated them Akata-LMP2BshRNA-pool 1, -pool 2
and -pool 3. We designed a control vector to encode a
nonsense (scr) shRNA and generated Akata-scrshRNA cells
in the same way as Akata-LMP2BshRNA cells.
To assess the efficiency and specificity of LMP2B silencing,
we isolated total RNA from Akata-LMP2BshRNA and
control Akata-scrshRNA cells. After cDNA synthesis, we
used quantitative real-time (qRT)-PCR (Taqman) target-
ing an LMP2B-specific sequence (available upon request)
to determine LMP2B mRNA expression levels. Results were
normalized to housekeeping gene hydroxymethylbilane
synthase (HMBS) mRNA expression, resulting in DCt
(cycle threshold) values. Akata cells are considered to be
in latency I (EBNA1 expression only). However, even
though no LMP2 protein can be detected, we observed low
but significant levels of LMP2A and LMP2B mRNA
expression (Ct range, 32–34; data not shown). Silencing
of LMP2B in the three Akata-LMP2BshRNA cell pools showed
LMP2B mRNA expression levels to be 25.3±2.3% of those
of Akata-scrshRNA cells (Fig. 1a), but there was no change in
LMP2AmRNA expression (not shown). The lack of available
anti-LMP2B antibody precluded substantiation of the above
qRT-PCR data by immunoblotting. Nevertheless, we con-
sidered the degree of silencing sufficient for our purposes,
and the consistency of the degree of silencing justified the
use of Akata-LMP2BshRNA-pools 1, 2 and 3 as biological
replicates in all subsequent experiments.
EBV lytic replication is initiated by upregulation of BZLF1.
Thus, based on own previous observations (Bernasconi
et al., 2006), we determined BZLF1 mRNA expression
levels before and 6, 24, 48 and 72 h after BCR cross-linking
by using qRT-PCR. DCt values from unstimulated cells
were subtracted from DCt values from stimulated cells,
resulting in DDCt values. mRNA expression of the vector
control was set to 100% and the percentages of reduction of
mRNA expression in LMP2B-silenced cells were evaluated.
BZLF1 mRNA levels in LMP2B-silenced Akata-LMP2BshRNA
cells were 25–35% of those in control Akata-scrshRNA cells
from 6 to 72 h after BCR cross-linking (Fig. 1b). Using
flow cytometry, we found similar frequencies of surface
IgG-positive cells in Akata-LMP2BshRNA and Akata-scrshRNA
Table 1. Characteristics of Akata cells used for silencing and overexpression experiments
wt, Wild type; shRNA, short hairpin RNA; ect, ectopic; EGFP, enhanced green fluorescent protein; sIgG, surface IgG; NM, not measured.
Experiment Cell line Vector
construct
EGFP+
(%)*
sIgG+
(%)*
gp350/220 staining (% of cells)*
0 h 24 h
Stimulated Unstimulated
Akatawt None NM 96 – – –
Silencing
Vector control Akata-scrshRNA pSICOR-scrRNA 99 91 0.3±0.1 1.7±0.5 0.5±0.2
LMP2B pool 1–3 Akata-LMP2BshRNA pSICOR-LMP2B-68 99±1 90±4 0.2±0.2 0.3±0.1 0.2±0.1
LMP2A pool 1–3 Akata-LMP2AshRNA pSICOR-LMP2A 99±1 84±3 1.2±0.6 2.2±0.3 1.1±0.5
Overexpression
Vector control Akata-neoect pEneo NM 91 – – –
LMP2A Akata-LMP2Aect pEneo-LMP2A NM 92 – – –
*Values are presented as means±SD.
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cells (Table 1). This excluded the possibility that the
differences in BZLF1 mRNA expression levels upon BCR
cross-linking were due to differences in surface IgG
expression. Thus, the reduced BZLF1 mRNA expression in
Akata-LMP2BshRNA cells was probably a direct consequence
of LMP2B silencing.
To substantiate the above qRT-PCR results, we stained
Akata-LMP2BshRNA and Akata-scrshRNA cells before and 24 h
after BCR cross-linking with a fluorescein isothiocyanate-
labelled antibody against EBV late lytic gp350/220 protein
in three independent experiments performed in triplicate
(Table 1). Both unstimulated Akata-LMP2BshRNA and
Fig. 1. LMP2B silencing, LMP2A overexpression and LMP2A silencing in Akata cells and impact on activation of EBV lytic
replication upon BCR cross-linking. (a) Validation of LMP2B silencing: expression of LMP2B in Akata-LMP2BshRNA cells was
measured by qRT-PCR. Data were normalized to those for HMBS, and expression of control Akata-scrshRNA cells was set to
100% (means and SD of pools). (b) Impact of LMP2B silencing on activation of EBV lytic replication upon BCR cross-linking.
Cells (0.5106) were seeded and treated with or without polyclonal rabbit anti-human IgG (0.1 mg ml”1) for 3 h. After
stimulation, cells were centrifuged and suspended in fresh medium. Immediate-early lytic BZLF1 mRNA levels were measured
at the indicated times before and after BCR cross-linking with a specific Taqman system. The mRNA expression of control
Akata cells was set to 100% for each time point, and the percentage reduction of mRNA expression in LMP2B-silenced Akata
cells was evaluated. One representative experiment of three carried out in triplicate is shown. (c) LMP2B silencing in Akata cells
resulted in decreased activation of lytic EBV 24 h after BCR cross-linking. Data shown represent the means and SD of three
independent experiments. (d, e) Validation of LMP2A overexpression by (d) immunoblotting and (e) immunostaining.
Immunoreactive proteins were detected by the specific rat anti-LMP2A antibody 8C3. (f) Expression of EBV immediate-early
lytic BZLF1 mRNA in Akata-LMP2Aect cells showed a decrease 24 h after BCR cross-linking compared with control. Means
and SD of three independent stimulations are shown. (g) Validation of LMP2A silencing by qRT-PCR in Akata-LMP2AshRNA cells
(mean and SD of pools) and Akata-scrshRNA cells. (h) LMP2A silencing in Akata-LMP2AshRNA cells resulted in increased
activation of EBV lytic replication 24 h after BCR cross-linking. Data shown represent the means and SD of three independent
experiments.
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Akata-scrshRNA cells showed a similar low basal percentage
of cells staining for gp350/220 (mean±SD, 0.3±0.1%).
Consistent with the qRT-PCR data, 24 h after BCR cross-
linking, Akata-LMP2BshRNA cells showed a 4- to 5-fold
lower number of cells positive for gp350/220 than Akata-
scrshRNA cells (0.3±0.1% versus 1.7±0.5%). Thus, upon
BCR cross-linking, induction of EBV lytic replication in
LMP2B-silenced Akata-LMP2BshRNA cells is lower than in
Akata-scrshRNA cells, not only at the mRNA expression
level of the immediate-early lytic gene BZLF1, but also at
the level of the late lytic protein gp350/220, indicating a
reduced susceptibility of LMP2B-silenced EBV-harbouring
cells to activation of EBV lytic replication.
Next, we reasoned that if LMP2B regulates LMP2A
negatively, which prevents activation of lytic EBV, over-
expression of LMP2A should yield outcomes similar to
those of LMP2B silencing. Therefore, we amplified the
sequence encoding LMP2A from the vector pSG5-LMP2
(Sample et al., 1989) by PCR and cloned the PCR product
via PmeI/XhoI into the Moloney murine leukemia virus-
derived pEneo bicistronic expression vector containing an
internal ribosome entry site with a neomycin selection
marker (Schaefer et al., 2001). Positive clones were verified
by sequencing. The parental pEneo plasmid was used as
control vector. Akatawt cells were transfected by electro-
poration with the pEneo-LMP2A expression vector or the
parental vector pEneo. After 2 days recovery, the trans-
fected cells were subjected to G418 selection. Stably trans-
fected cells emerged after 2–3 weeks. Expression of LMP2A
mRNA was confirmed by qRT-PCR (not shown) and
immunoblotting showing expression of the correct-sized
protein at 43 kDa (Fig. 1c). These cells were named
Akata-LMP2Aect, and the control cells Akata-neoect (Table 1).
Immunofluorescence staining showed expression of LMP2A
in all Akata-LMP2Aect cells, with heterogeneous high and low
LMP2A expression levels reflecting a polyclonal population
(Fig. 1d), but no expression in the control Akata-neoect cells
(not shown). These populations showed no up- or down-
regulation of LMP2B mRNA expression by qRT-PCR (not
shown) and similar levels of surface IgG (Table 1),
confirming that LMP2A overexpression had not affected
LMP2B mRNA or surface IgG expression.
To compare susceptibility to activation of lytic EBV in
LMP2A-overexpressing Akata cells with the above-assessed
activation in LMP2B-silenced Akata cells, we stimulated
Akata-LMP2Aect and control Akata-neoect cells by BCR
cross-linking. We chose 24 h after BCR cross-linking for
the comparison because LMP2B-silenced Akata and control
cells had shown a suitable difference in BZLF1 mRNA
expression at 24 h (Fig. 1b, c). Stimulated and unstimu-
lated Akata cells were collected and examined by qRT-PCR
for BZLF1 mRNA expression. The data were normalized to
HMBS mRNA and further normalized to mRNA levels in
unstimulated cells as mentioned above. The results are
presented as ratios of stimulated over unstimulated Akata
cells. As expected from published data (Fukuda &
Longnecker, 2005; Konishi et al., 2001), BZLF1 mRNA
expression in LMP2A-overexpressing cells was reduced to
3.3±5.7% of that in control cells in three independent
experiments (Fig. 1f). This superior reduction, compared
with the reduction to 33.3±6.7% seen in LMP2B-silenced
cell pools (Fig. 1c), was probably intrinsic to the nature
of the experiments, with overexpression of LMP2A being
more effective than LMP2B silencing. Nevertheless, the
reduced BZLF1 mRNA expression upon BCR cross-linking
in EBV-harbouring LMP2B-silenced and LMP2A-over-
expressing cells indicated that LMP2B modulates LMP2A
negatively in preventing activation of EBV lytic replication.
To verify our results by using an opposite approach, we
constructed a silencing pSICOR vector specific for LMP2A,
targeting exon 1 of LMP2A (Stewart et al., 2004), and
transduced it virally into Akatawt cells as described above
for LMP2B silencing to obtain pools 1, 2 and 3 of Akata-
LMP2AshRNA cells (Table 1). Akata-LMP2AshRNA cell pools
showed LMP2A mRNA expression levels of 15.9±11.1%
of those in control cells (Fig. 1g), but no effect on LMP2B
mRNA expression levels (not shown), confirming the
specificity of silencing. To assess the effect of LMP2A
silencing on induction of EBV lytic replication, we
measured BZLF1 mRNA expression levels 24 h following
BCR cross-linking in the three biological replicates and
compared the levels with those in the corresponding
control cells. Activation of EBV lytic replication in LMP2A-
silenced cells was 2- to 6-fold higher than in control cells,
as illustrated by the increase of BZLF1 mRNA to 552.3±
89.9% compared with vector-control Akata-scrshRNA cells
(Fig. 1h). Increased activation of EBV lytic replication in
LMP2A-silenced cells was confirmed at the protein level by
the measurement of the expression of gp350/220 in Akata-
LMP2AshRNA cells (Table 1). Akata-LMP2AshRNA cells
expressed higher basal levels of gp350/220 before stimula-
tion (1.2±0.6%) and at 24 h unstimulated (1.1±0.5%)
than did Akata-scrshRNA cells (0.3±0.1 and 0.4±0.2%,
respectively). Twenty-four hours after stimulation, the
detected envelope protein reached levels of up to 2.2±
0.3% in Akata-LMP2AshRNA-pool 1 cells, compared with
1.7±0.5% of Akata-scrshRNA cells. Thus, stimulated Akata-
LMP2AshRNA cells show a 1.3-fold increase of gp350/220
expression compared with Akata-scrshRNA cells, similar to
the data obtained from qRT-PCR. This indicates that
silencing of LMP2A increases the susceptibility to activa-
tion of EBV lytic replication. Therefore, silencing of
LMP2B and LMP2A exhibits opposite effects on suscept-
ibility to activation of EBV lytic replication.
LMP2A plays a relevant role in controlling the switch from
EBV latency to lytic replication in B cells through modula-
tion of the activity of cellular kinases, including the Src family
of phosphotyrosine kinases (Mancao et al., 2005; Portis et al.,
2004), and calcium mobilization following BCR cross-
linking. This results in a decreased activation of lytic EBV.
LMP2B lacks an N-terminal signalling domain and cannot
therefore influence any signalling cascade directly. Rovedo &
Longnecker (2007) showed that LMP2B and LMP2A can
interact with each other in the EBV-negative BL cell line
LMP2B silencing reduces lytic EBV activation
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BJAB, resulting in decreased phosphorylation of the LMP2A
cytoplasmic N-terminal domain and the block of cytoplas-
mic calcium release upon BCR cross-linking.
Here, we show that silencing of LMP2B reduces activation
of EBV lytic replication in the BL cell line Akata, as does
overexpression of LMP2A. This indicates that LMP2B
decreases the block of LMP2A on BCR activation. In
contrast, specific silencing of LMP2A in Akata cells had
exactly the opposite effect of increasing induction of lytic
EBV replication upon stimulation, as documented by
BZLF1 mRNA expression and gp350/220 protein expres-
sion. Hence, given that LMP2A prevents lytic EBV
activation (Miller et al., 1994b, 1995), our results support
the notion that LMP2B negatively affects LMP2A regula-
tion of activation of lytic EBV upon BCR cross-linking.
Akata cells are known to maintain latency I in culture
(Takada, 1984) and express low levels of LMP2A (Konishi
et al., 2001), and are negative for LMP2A protein expres-
sion when probed by immunoblotting. More sensitive tools
like Southern–PCR (Tao et al., 1998) or qRT-PCR, as
shown here, are able to detect low mRNA expression levels
of both LMP2A and LMP2B in exponentially growing
Akata cells. We were able to detect LMP2A after immuno-
precipitation of resting Akatawt cells, but could not observe
any quantitative changes upon activation of lytic EBV (M.
Bernasconi & J. A. Sigrist, unpublished observation). Low
levels of LMP2A do not seem sufficient to block activation
upon BCR cross-linking in Akata cells (Konishi et al.,
2001). However, our results indicate that, for as low as the
protein expression level is, both LMP2A and LMP2B
influence the susceptibility to activation of lytic EBV
infection.
In conclusion, our results suggest that LMP2B adds a novel
layer of complexity to the regulation of lytic EBV infection
in B cells. Together with the observations made in the EBV-
negative cell line BJAB (Rovedo & Longnecker, 2007), we
suggest that LMP2B under some circumstances impacts on
the activity of LMP2A, resulting in increased susceptibility
to activation of lytic EBV replication through modulation
of BCR and downstream signalling.
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Abstract
The B-lymphotropic Epstein-Barr virus (EBV) encodes two isoforms of the latent membrane 
protein 2 (LMP2), LMP2A and LMP2B, which are expressed during latency in B-cells. The 
function of LMP2B is largely unknown, whereas LMP2A blocks B-cell receptor (BCR) 
signaling transduction and induction of lytic EBV infection, thereby promoting B-cell 
survival. Transfection experiments of LMP2B in EBV-negative B-cells and the silencing of 
LMP2B in EBV-harboring Burkitt’s lymphoma-derived Akata cells suggest that LMP2B 
interferes with the function of LMP2A, but the role of LMP2B in the presence of functional 
EBV has not been established. Here, LMP2B, LMP2A, or both were overexpressed in EBV-
harboring Akata cells to study the function of LMP2B. Overexpression of LMP2B increased 
the magnitude of EBV switching from its latent to its lytic form upon BCR cross-linking, as 
indicated by a more enhanced upregulation and expression of EBV lytic genes and 
significantly increased production of transforming EBV compared to Akata vector control 
cells or LMP2A overexpressing cells. Moreover, LMP2B lowered the degree of BCR cross-
linking required to induce lytic EBV infection. Finally, LMP2B co-localized with LMP2A as 
demonstrated by immunoprecipitation and immunofluorescence and restored calcium 
mobilization upon BCR cross-linking, a signaling process inhibited by LMP2A. Thus, our 
findings suggest that LMP2B negatively regulates the function of LMP2A in preventing the 
switch from latent to lytic EBV replication.
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The B-lymphotropic Epstein-Barr virus (EBV) encodes two isoforms of latent membrane protein 2 (LMP2),
LMP2A and LMP2B, which are expressed during latency in B cells. The function of LMP2B is largely unknown,
whereas LMP2A blocks B-cell receptor (BCR) signaling transduction and induction of lytic EBV infection,
thereby promoting B-cell survival. Transfection experiments on LMP2B in EBV-negative B cells and the
silencing of LMP2B in EBV-harboring Burkitt’s lymphoma-derived Akata cells suggest that LMP2B interferes
with the function of LMP2A, but the role of LMP2B in the presence of functional EBV has not been established.
Here, LMP2B, LMP2A, or both were overexpressed in EBV-harboring Akata cells to study the function of
LMP2B. The overexpression of LMP2B increased the magnitude of EBV switching from its latent to its lytic
form upon BCR cross-linking, as indicated by a more-enhanced upregulation and expression of EBV lytic genes
and significantly increased production of transforming EBV compared to Akata vector control cells or LMP2A-
overexpressing cells. Moreover, LMP2B lowered the degree of BCR cross-linking required to induce lytic EBV
infection. Finally, LMP2B colocalized with LMP2A as demonstrated by immunoprecipitation and immuno-
fluorescence and restored calcium mobilization upon BCR cross-linking, a signaling process inhibited by
LMP2A. Thus, our findings suggest that LMP2B negatively regulates the function of LMP2A in preventing the
switch from latent to lytic EBV replication.
Epstein-Barr virus (EBV) is a ubiquitous B-lymphotropic
gammaherpesvirus which persists after primary infection la-
tently in the host for life and may switch periodically to its lytic
form (28). In vitro, EBV undergoes very efficient growth trans-
formation and immortalizes infected B cells by latent infection,
resulting in lymphoblastoid cell lines (LCLs) expressing a lim-
ited number of viral genes, including six viral nuclear antigens
(EBNAs) and latent membrane protein 1 (LMP1) and LMP2
(30). The ability to transform B cells implicates EBV as the
culprit for a variety of malignancies, including Burkitt’s lym-
phoma, Hodgkin’s disease, and posttransplant lymphoprolif-
erative disease (8, 24, 38). In vivo, EBV persists in latently
infected memory B cells circulating in the peripheral blood
(30). These latently infected cells do not express EBNAs or
LMP1, but may express LMP2 (1, 2). Since LMP2 has no
transformation capacity (12), this may suggest a pivotal role of
LMP2 in the regulation of the balance between latent and lytic
EBV.
Transcription of LMP2 is controlled by two promoters sep-
arated in the viral DNA by 3 kb (31). Two mRNAs that have
different 5 exons followed by eight common exons encode two
distinct proteins, LMP2A and LMP2B, respectively. LMP2A
contains an N-terminal cytoplasmic domain of 119 amino acids
with eight tyrosines that are phosphorylated in LCLs, 12 trans-
membrane domains, and a C-terminal domain of 12 amino
acids. LMP2A blocks B-cell receptor (BCR) signal transduc-
tion through specific phosphotyrosine motifs in its N-terminal
domain and promotes B-cell survival. This function is depen-
dent on the expression level of LMP2A (1, 2, 5, 6, 15, 21, 35).
LMP2B lacks the entire N-terminal cytoplasmic domain. A
recent work using transfection of LMP2 into EBV-negative
cells has suggested possible roles for LMP2B. LMP2B colocal-
ized with LMP2A in the membrane where the C terminus of
both splice variants can interact and regulate the activity of
each other (17). Furthermore, LMP2B was shown to negatively
regulate LMP2A activity by interfering with its aggregation
(29). Another study revealed protein domains of LMP2B
which are required for intra- and extracellular localization and
self-aggregation (37), which raised the question of whether the
function of LMP2B in EBV is bound to its localization inde-
pendently of LMP2A. Nevertheless, whether and how LMP2B
is involved in the regulation of latent and lytic EBV infection
in B cells harboring the functional virus remains a largely
unresolved question.
Burkitt’s lymphoma-derived Akata cells provide an optimal
model to study the balance between latent and lytic EBV.
Specifically, lytic EBV infection can be initiated in Akata cells
by cross-linking their BCR using anti-immunoglobulin G (anti-
IgG) (36). Importantly, upon induction of lytic EBV infection,
the majority of viral genes are expressed (3, 39). Since these
EBV genes could have an impact on the function of LMP2B,
we used Akata cells to investigate the function of LMP2B in
cells harboring functional EBV. Recently, we found that the
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silencing of LMP2B reduces susceptibility to induction of lytic
EBV infection upon BCR cross-linking (27). This result indi-
cated a role of LMP2B distinct from that of LMP2A in the
regulation of EBV lytic activation. In this work, we further
pursue the hypothesis that LMP2B exhibits a negative-regula-
tory effect on LMP2A maintenance of EBV latency. Thus, we
compared the effects of overexpression of LMP2B and LMP2A
on the susceptibility to induction of lytic EBV infection and on
cellular signaling pathways in Akata cells.
MATERIALS AND METHODS
Cell lines and primary cells. The Burkitt’s lymphoma cell line Akata (36) was
grown in RPMI 1640 supplemented with 10% fetal calf serum, L-glutamine (2
mM), penicillin (100 U/ml), and streptomycin (100 g/ml). Akata cells were a
kind gift of A. Bell (Birmingham, United Kingdom). Akata cells transfected with
the plasmids pEneo (33), pEneo-LMP2A (27), and pEneo-FLAG-LMP2B,
named Akata-vector (27), Akata-LMP2A (27), and Akata-LMP2B pools 1 to 3,
respectively, were cultured in the same medium supplemented with 0.4 mg/ml
G418 (Promega, Mannheim, Germany). Akata-cre cells that stably overexpress
the regulatable creERT2 recombinase (9) integrated into the vector pcDNA3.1
were cultured in the same medium supplemented with 0.4 mg/ml G418 (Pro-
mega, Mannheim, Germany). Cord blood mononuclear cells (CBMC) were
obtained from heparinized blood by Ficoll-Hypaque gradient centrifugation
(Amersham Biosciences Europe GmbH, Otelfingen, Switzerland) and washed
with phosphate-buffered saline (Gibco, Invitrogen Life Sciences, Basel, Switzer-
land). Informed consent was obtained from parturient women. The Zurich in-
stitutional ethics committee approved the collection and use of clinical material.
B95.8 cells were cultured in Dulbecco’s minimal essential medium supplemented
with 10% fetal calf serum, L-glutamine (2 mM), penicillin (100 U/ml), and
streptomycin (100 g/ml) (23).
Plasmids. The sequence coding for LMP2B was PCR amplified from the
vector pSG5-LMP2 (15, 31) with following primers, including cloning adapters
and 3 FLAG for LMP2B tagging: FLAG-LMP2B-F (5-CGCGTTTAAACAT
GGACTACAAAGACCATGACGGTGATTATAAAGATCATGATATCGAT
TACAAGGATGACGATGACAAGAATCCAGTATGCCTGCCTG-3) and
LMP2-Rev (5-GCGCTCGAGTTATACAGTGTTGCGATATGGGGTC-3).
The PCR product was cloned via PmeI/XhoI into the Moloney murine leukemia
virus-derived pEneo bicistronic expression vector containing an internal ribo-
some entry site with a neomycin selection marker (33), resulting in the vectors
pEneo-FLAG-LMP2B and pEneo-LMP2A (27). Positive clones were verified by
sequencing. The parental pEneo plasmid was used as the control vector.
Transfection. Cells (1  106) were electroporated with 2 g of the pEneo,
pEneo-LMP2A, or pEneo-FLAG-LMP2B plasmid with Nucleofector II (Amaxa
GmbH, Cologne, Germany) with Buffer T and the program A-23. Electroporated
cells were allowed to recover for 2 days and were then selected with 0.8 mg/ml
G418 (Promega) for 2 to 3 weeks until resistant cells arose. These cells were
named Akata-vector, Akata-LMP2A, and Akata-LMP2B pools 1 to 3, respec-
tively. One month after selection, cells were supplemented with 0.4 mg/ml G418
and used for experiments. To generate double-transfected Akata cells, either
stable Akata-LMP2B cells were electroporated transiently (t) with the vector
pEneo-LMP2A (named 2B  At) or Akata-LMP2A cells were electroporated
transiently with the vector pEneo-FLAG-LMP2B (named 2A  Bt).
Immunoblot analysis. Total cellular protein extracts were prepared by disrup-
tion of cells in radioimmunoprecipitation assay lysis buffer (150 mM NaCl, 1%
NP-40, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate [SDS], and 50 mM Tris,
pH 7.5). After denaturation for 10 min in 4 loading LDS buffer (Invitrogen,
Basel, Switzerland), samples were separated on a 10% Bis-Tris gel (Invitrogen)
and transferred to a nitrocellulose membrane (Schweitzer & Schell Bioscience
GmbH, Dassel, Germany). Membranes were blocked with 5% low-fat milk in 1
phosphate-buffered saline (PBS)–0.1% Tween 20 and incubated with either
mouse anti-FLAG M2 (Sigma, St. Louis, MO), rat anti-LMP2A (clone 14B7) (5),
or anti-c-myc (A-14; Santa Cruz Biotech, Inc., Santa Cruz, CA) antibody over-
night at 4°C. Immunoreactive proteins were detected by the secondary antibodies
against mouse and rabbit, respectively (Cell Signaling Technology, Danvers,
MA) and an enhanced chemiluminescence detection kit (SuperSignal West
Femto; Perbio Science Switzerland S.A., Lausanne, Switzerland).
IP. Total cellular protein extracts were prepared by disruption of 5  106 cells
in Tris nondenaturing lysis buffer (150 mM NaCl, 1% Triton X-100, 1 mM
EDTA, and 50 mM Tris, pH 7.5), 2 mM NaF, and 2 mM Orthovanadate (all from
Sigma). Isolated proteins were immunoprecipitated with a Sigma immunopre-
cipitation (IP) kit according to the manufacturer’s instructions. IPs were per-
formed with the same antibodies used for immunoblotting or without an anti-
body.
Immunostaining. Cells (5  104) were centrifuged by Cytospin on double
Cytofunnel glass slides (Thermo, Waltham, MA) and fixed with methanol for 10
min at 20°C. Cells were permeabilized with 1% Triton X-100 in 1 PBS for 20
min at room temperature. Immunoreactive proteins were detected with a rat
anti-LMP2A antibody, 14B7 (1:100), and a secondary Alexa 488-labeled goat
anti-rat IgG antibody diluted 1:200 (Molecular Probes, Invitrogen). FLAG-
tagged LMP2B was detected with anti-FLAG M2 from Sigma (1:500) and a
secondary Alexa 594-labeled goat anti-mouse IgG antibody diluted 1:200 (Mo-
lecular Probes, Invitrogen). BZLF1 was detected with anti-BZLF1 (Argene,
North Massapequa, NY) diluted 1:100 and probed with the same secondary
antibody used for FLAG detection.
Flow cytometry. To evaluate the surface IgG (sIgG) content of transfected
cells for later stimulation experiments with BCR cross-linking, cells were fixed in
4% paraformaldehyde (Sigma) and stained with a phycoerythrin-labeled anti-
human IgG1, antibody (BD Biosciences, Basel, Switzerland). A phycoerythrin-
labeled anti-mouse IgG1, antibody (BD Biosciences) was used as an isotype
control. To determine the percentage of cells in which EBV was activated by
BCR cross-linking, 0.5 106 cross-linked and non-cross-linked cells were stained
with a fluorescein isothiocyanate (FITC)-labeled antiviral gp350/220 antibody
diluted 1:10 (Biodesign International, Saco, ME) and analyzed by flow cytometry
(FC-500; Beckmann-Coulter, Krefeld, Germany).
BCR cross-linking of Akata cells. Akata cells were split to 0.5  106 cells/ml
24 h before BCR cross-linking. Cells (0.5  106/ml) were then BCR cross-linked
with 0.1 g/l polyclonal rabbit anti-human-IgG (Dako, Zug, Switzerland) for
3 h and suspended afterwards in fresh RPMI 1640. Cross-linked and non-cross-
linked cells were collected for subsequent analyses.
qRT-PCR. Total RNA was extracted from 0.5  106 cells with an RNeasy kit
from Qiagen (Hombrechtikon, Switzerland). DNase [DNA-free; Ambion (Eu-
rope), Huntington, Cambridgeshire, United Kingdom] treatment was performed
before cDNA synthesis with an Omniscript RT kit (Qiagen). Quantitative real-
time PCR (qRT-PCR) was done with validated TaqMan systems for the house-
keeping gene HMBS and the lytic EBV genes BZLF1, BXLF1, and LMP2 (14) on
an ABI 7200 (Applied Biosystems). TaqMan data were analyzed using SDS 2.2
(Applied Biosystems), and mRNA expression was normalized to HMBS mRNA,
resulting in threshold cycle (CT) values. CT values were further normalized by
dividing “cross-linked” by “not cross-linked” values, resulting in CT values.
qRT-PCR data for control vector CT were set to 100% and LMP2B- or
LMP2A-overexpressing cells were compared to it.
Transformation assay. Fifty thousand freshly isolated CBMC per well were
seeded in a 96-well plate. Culture supernatants were filtered through a 0.45-m
polyvinylidene difluoride Millex-HV filter (Millipore Corporation, MA). Fifty
microliters of filtered culture supernatant of cells 24 h after anti-IgG cross-
linking or no cross-linking was added to a final volume of 100 l per well. A total
of 10 wells for each filtered culture supernatant was plated and inoculated.
Filtered supernatant from B95.8 served as the positive control, whereas the
negative control was CBMC cultured with medium only (23). The transformation
capacity was monitored by counting the wells after 6 weeks, when growth and
clustering of cells could be observed (34). The percentage of transformation was
calculated by setting 10 transformed wells to 100% and by normalization to the
transformation capacity of the supernatant of cells that were not cross-linked,
representing the spontaneous activation of EBV in Akata cells. Statistics were
done with Prism 4 (GraphPad Software, Inc.).
Calcium mobilization. Cells (5  106) were stained with Fluo-3 (6 M final
concentration) and Fura-Red (15 M final concentration; both from Invitrogen)
for 45 min in RPMI 1640 at 37°C. After a washing step with 1 PBS, cells were
stored at room temperature in the dark. Before measurement, cells were incu-
bated for 5 min at 37°C. Calcium mobilization was measured by adding ionomy-
cin (2 g/ml final concentration; Invitrogen) as the control and anti-IgG at the
same concentration as in stimulation experiments (100 g/ml) by using a FC-500
(Beckmann-Coulter) with an argon laser at 488 nm. Fluorescent emission was
recorded at 520 nm (Fluo-3) and 670 nm (Fura-Red), and the Fluo-3/Fura-Red
ratio was plotted against time. The baseline was recorded prior to anti-IgG
addition for 30 s and for 5 min after BCR cross-linking. The increase over the
baseline level was calculated for the time of peak of calcium mobilization (tp) by
using FlowJo 5.7.2 software. The percentage of responding cells was calculated
for the time slice from tp to tp  2 min. As an additional control, Akata-cre cells
were stimulated and the calcium mobilization was measured.
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RESULTS
Construction of LMP2B-overexpressing Akata cells. In or-
der to investigate the effects of LMP2B on LMP2A and the
switch from latent to lytic EBV replication, we first constructed
EBV-harboring Akata cells overexpressing either LMP2B or
LMP2A (27) and Akata cells with the vector control (27).
Given that no specific antibody against LMP2B exists, we
chose to tag LMP2B with a 3 FLAG sequence at the N
terminus. The tag was placed at the N terminus, since it has
been suggested that clustering of LMP2A and LMP2B occurs
over the common C termini and that LMP2B influences the
activity of its LMP2A isoform only when they colocalize (18,
29). As the transfection efficiency of B cells is low with com-
mon protocols, we decided to establish Akata cell pools stably
overexpressing LMP2B, LMP2A, or a control vector. Thus,
Akata cells were transfected independently with pEneo-
FLAG-LMP2B, pEneo-LMP2A, or the control vector pEneo
alone, as described in Materials and Methods. After neomycin
selection, stable overexpression of LMP2B was verified for all
three independently transfected Akata cell pools at the RNA
level by qRT-PCR and at the protein level by immunoblotting
and immunostaining. The three LMP2B-overexpressing cell
pools (Akata-LMP2B pools 1, 2, and 3) showed different levels
of overexpression of LMP2B after transfection (Fig. 1A). The
mRNA expression levels correlated with protein levels,
whereby Akata-LMP2B pool 1 showed a medium level, pool
2 a high level, and pool 3 the lowest level of LMP2B mRNA
and protein, respectively (Fig. 1B). Immunostaining was done
with Akata-LMP2B pool 2. Most overexpressed LMP2B local-
ized to cytosolic compartments, whereas smaller amounts were
detected in the plasma membrane (Fig. 1C). Furthermore, all
cell lines were stained for sIgG and were found to express sIgG
in similar percentages (Table 1). Thus, similar prerequisites for
susceptibility to stimulation by BCR cross-linking with anti-
IgG were ensured in the distinct cell lines.
LMP2B overexpression increases the magnitude of EBV
lytic activation after BCR cross-linking. To assess the distinct
effects of LMP2B and LMP2A on lytic activation of EBV in
FIG. 1. Generation of LMP2B-overexpressing Akata cells. (A) Overexpression of LMP2B pools 1 to 3 (2B-1, 2B-2, 2B-3) by qRT-PCR using
specific TaqMan systems targeting HMBS and LMP2 mRNA, respectively. (B) Immunoblot of FLAG-LMP2B pools 1 to 3 (2B-1, 2B-2, 2B-3).
(C) Immunostaining of FLAG-LMP2B in Akata-vector control cells and Akata-LMP2B pool 2 (2B-2).
TABLE 1. Characteristics of Akata cells useda
Cell line Vector construct % sIgG cells
% Cells activated by gp350/220 staining
0 h
24 h
Cross-linked Not cross-linked
Akatab None 96  1 ND ND ND
Akata-vectorb pEneo 92  2 0.30  0.11 4.62  0.06 0.58  0.09
Akata-LMP2Bc pEneo-FLAG-LMP2B 88  4 0.36  0.20 5.42  0.94 0.69  0.23
Akata-LMP2Ab pEneo-LMP2A 92  1 0.24  0.05 1.00  0.81 0.34  0.13
a ND, not detected.
b Values are presented as means  SD from three independent experiments.
c Values are presented as means  SD from pools 1 to 3.
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Akata cells, we stimulated Akata-LMP2B cells or Akata-
LMP2A cells and the corresponding Akata-vector control cells
by BCR cross-linking. After 24 h, cross-linked and non-cross-
linked cells were collected and examined by qRT-PCR for
expression of the immediate-early lytic gene BZLF1 and the
early lytic gene BXLF1 encoding the viral thymidine kinase.
The data were normalized to HMBS mRNA expression and
are presented as ratios of cross-linked to non-cross-linked cells
(Fig. 2). Akata-LMP2B cells showed mRNA expression levels
of BZLF1 and BXLF1 that increased 4-fold and 55-fold, re-
spectively (Fig. 2A). By contrast and as expected, transcription
levels of lytic EBV genes were reduced in Akata-LMP2A cells,
where expression of BZLF1 and BXLF1 mRNAs was reduced
by 97% and 99%, respectively (Fig. 2B). To confirm these
results at the protein level, we stained cells before and 24 h
after BCR cross-linking with a FITC-labeled antiviral gp350/
220 antibody in three independent stimulations. Indeed, as
determined by flow cytometry, Akata-LMP2B cell pools ex-
pressed up to 5.4-fold- and 4.6-fold-higher gp350/220 levels
than Akata-LMP2A cells and Akata-vector control cells, re-
spectively (Fig. 2C; Table 1).
LMP2B-overexpressing Akata cells produce more infectious
EBV than control cells upon BCR cross-linking. To verify the
complete activation of the EBV lytic cycle following BCR
cross-linking, the production of infectious EBV was monitored
by the transformation of primary human B cells (34). Follow-
ing BCR cross-linking of Akata-LMP2B, Akata-LMP2A, and
Akata-vector control cells, supernatants were prepared from
three independent experiments and added to freshly isolated
CBMC to determine the transformation capacity of the infec-
tious EBV produced. After normalization to non-cross-linked
cells, the transformation capacities of supernatants from
Akata-vector control cells were 67%, but those from Akata-
LMP2B-cell pools were up to 100% (P 	 0.0356), in contrast
to the 0% transformation capacity of supernatants from Akata-
LMP2A cells (P 	 0.0089; Fig. 3).
Overexpression of LMP2B decreases the degree of BCR
stimulation required to induce lytic EBV infection, in contrast
to overexpression of LMP2A. LMP2A blocks BCR signaling,
thereby impeding EBV lytic activation (6). It is not clear how
the expression level of LMP2A influences the degree of BCR
cross-linking (BCR activation) required to induce lytic EBV
infection and how this is affected by LMP2B overexpression.
Therefore, we assessed the magnitude of EBV lytic activation
as a function of the anti-IgG dose to engage BCR by cross-
linking Akata-vector, Akata-LMP2B, or Akata-LMP2A cells
with increasing concentrations of anti-IgG. To quantify the
activation of EBV lytic infection, mRNA expression of BZLF1
FIG. 2. LMP2B overexpression increases the magnitude of EBV lytic activation after BCR cross-linking, whereas LMP2A overexpression
results decreased magnitude. qRT-PCR with specific systems for HMBS, BZLF1, and BXLF1 mRNA, respectively, for Akata-vector control,
Akata-LMP2B (A), and Akata-LMP2A (B) 24 h after BCR cross-linking. Means and standard deviations (SD) of qRT-PCR results are from three
independent stimulation experiments on one representative polyclonal population. (C) Flow cytometry for gp350/220-FITC-labeled unstimulated
(gray line) or stimulated (black line) cells 24 h after BCR cross-linking. One representative measurement is shown for Akata-vector control,
Akata-LMP2B, and Akata-LMP2A cells with gp350/220-FITC-positive cells gated and indicated as percentages. Means and SD for three
independent experiments are summarized in Table 1.
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at 24 h after BCR cross-linking was measured (Fig. 4). Cross-
linked Akata-vector control cells compared to non-cross-
linked control cells showed an almost 100-fold increase of
BZLF1 mRNA expression with the lowest anti-IgG concentra-
tion of 5 g/ml and around 100-fold-higher peak BZLF1
mRNA expression levels with anti-IgG concentrations of 25
g/ml or higher. Akata-LMP2B cells showed a similar but
greater increase in BZLF1 mRNA expression and around five-
fold-higher peak levels than Akata-vector cells with anti-IgG
concentrations of 25 g/ml or higher. By contrast, Akata-
LMP2A cells required anti-IgG concentrations of at least 25
g/ml to show an increase in BZLF1 mRNA expression and an
anti-IgG concentration of 625 g/ml to show maximal BZLF1
mRNA expression levels, which were around 10-fold lower
than peak expression levels in Akata-vector cells. Thus, cells
with higher expression levels of LMP2A required higher doses
of anti-IgG to induce an EBV lytic activation, which was still of
a considerably lower magnitude than that for Akata-vector
control cells. These results suggest that the expression level of
LMP2A has an impact on the amount of BCR cross-linking
required to induce lytic EBV infection and that higher expres-
sion levels of LMP2A can be overridden, though only partially,
with a higher degree of BCR cross-linking. On the other hand,
higher LMP2B expression levels seemed to lower the degree of
BCR cross-linking required to induce EBV lytic activation and
to increase the magnitude of inducible EBV lytic activation.
LMP2B physically interacts with LMP2A before and after
BCR cross-linking in Akata cells. To investigate whether over-
expressed LMP2B physically interacts with endogenous
LMP2A, we isolated whole-cell protein extracts from Akata-
LMP2B pool 2 (2B-2) and Akata-vector control cells with a
subsequent pull-down IP of LMP2A. Subsequently, we per-
formed immunoblotting against FLAG tags and LMP2A (Fig.
5A). Indeed, coimmunoprecipitated LMP2B was detected by
anti-FLAG in Akata-LMP2B cells but not in Akata-vector
control cells, whereas endogenous LMP2A was detected in
both. Control IPs, with an anti-c-myc antibody or without an-
tibody and subsequent immunoblotting against c-myc or FLAG
(Fig. 5B and C) showed no unspecific pull-down, confirming
the specificity of the IPs, despite the overexpression of FLAG-
LMP2B.
Next, to elucidate in which compartment LMP2B and
LMP2A localize, we transfected Akata-LMP2A (2A) tran-
siently with FLAG-LMP2B (Bt) (indicated as 2A  Bt) and
immunostained LMP2A or FLAG-LMP2B for fluorescent mi-
croscopy. The images shown in Fig. 6B suggest partial colocal-
ization of both LMP2 isoforms in the same cellular compart-
ments (Fig. 6B). Additionally, we found an accumulation of
LMP2B in the cytosolic region, as seen in stable Akata-LMP2B
and described above (Fig. 1C). To determine if there is a
relocalization of LMP2A or LMP2B upon BCR cross-linking,
we double-stained Akata-LMP2A cells transiently transfected
with FLAG-LMP2B (2A  Bt) for FLAG-LMP2B and for
LMP2A (Fig. 6C), and for BZLF1 and LMP2A (Fig. 6D) after
BCR cross-linking. An immunofluorescence analysis indicated
a rather modest shift of LMP2A and LMP2B into the cytosol
after BCR cross-linking, but still-adequate amounts of both
LMP2s were located in the same compartments as before BCR
cross-linking.
LMP2B restores calcium mobilization in LMP2A-overex-
pressing Akata cells. It has been previously established that
LMP2A blocks calcium mobilization induced by BCR cross-
linking (20–22). To investigate the impact of LMP2B overex-
pression on calcium mobilization, we determined the calcium
levels before (baseline) and after BCR cross-linking, monitor-
ing the kinetics for 5 min in Akata-vector control, Akata-
LMP2B pool 2 (2B-2), and Akata-LMP2A (2A) cells, respec-
tively. Additionally, Akata-cre cells overexpressing creERT2
FIG. 3. More infectious EBV is produced in LMP2B-overexpress-
ing Akata cells than in the control. Isolated CBMC were infected with
supernatant from Akata-vector control, Akata-LMP2A, or Akata-
LMP2B pools 1 to 3 collected 24 h after stimulation by BCR cross-
linking. The transformation capacity was monitored by counting the
wells after 6 weeks, at which time growth and clustering of cells indi-
cated transformation. The percentage of transformation was calcu-
lated by setting 10 wells showing signs of transformation to 100% and
by normalization to the transformation capacity of the supernatant of
the corresponding BCR non-cross-linked control cells, representing
the spontaneous EBV lytic activation in Akata cells. Means and SD are
from three independent stimulation experiments with subsequent col-
lection of supernatant and infection of CBMC. t tests were performed
with a 95% confidence interval. *, no wells showed signs of transfor-
mation.
FIG. 4. Overexpression of LMP2B decreases the degree of BCR
stimulation required to induce lytic EBV infection, in contrast to
overexpression of LMP2A. BZLF1 mRNA expression in Akata-vector
control (f), Akata-LMP2A (F), or Akata-LMP2B (Œ) 24 h after BCR
cross-linking using increasing doses of anti-IgG. Means and SD are
from three independent stimulation experiments on one representative
polyclonal population.
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recombinase in the cytosol were stimulated and monitored in
parallel to exclude any epiphenomena due merely to overex-
pression which could influence calcium mobilization. Calcium
mobilization reached up to 3-fold, 3.3-fold, and 3.5-fold peaks
compared to baseline levels after BCR cross-linking in Akata-
vector control cells, Akata-cre cells, and Akata-LMP2B cells,
respectively (Fig. 7). Next, we generated double transfectants
by electroporation of Akata-LMP2B cells transiently with the
vector pEneo-LMP2A (2B  At) as described in Materials and
Methods and measured the calcium mobilization after BCR
cross-linking. We observed not only a decrease of calcium
mobilization from 3.5-fold to 1.9-fold in Akata-LMP2B cells
but also a decrease of responding cells from 90% to 74%.
These results are in agreement with previous studies (20–22).
The calcium mobilization in Akata-LMP2A cells revealed the
same low calcium mobilization and percentage of responding
cells as observed in the double-transfected 2B  At cells (1.8-
fold and 77%, respectively). To address the question of
whether it is possible to rescue the phenotype of Akata-vector
control cells, we transiently transfected Akata-LMP2A cells
with the vector pEneo-FLAG-LMP2B (2A  Bt). Interest-
ingly, the calcium mobilization was restored to Akata-vector
control cell levels from 1.8- to 2.9-fold after BCR cross-linking.
Additionally, responding cells increased from 77% to 82% in
double-transfected 2A  Bt cells (Fig. 7).
DISCUSSION
In this work, we investigated the impact of LMP2B on the
potential of LMP2A to maintain EBV in its latent state. We
demonstrate that LMP2B increases the magnitude of EBV
switching from its latent to its lytic form upon BCR cross-
linking, lowers the degree of BCR cross-linking required to
provoke this switching, and is involved in augmenting signaling
via calcium mobilization upon BCR cross-linking in Akata cells
harboring functional EBV. These observations suggest a neg-
ative regulatory effect of LMP2B on the ability of LMP2A to
block BCR signaling, thereby preventing EBV from switching
from latent to lytic infection in B cells.
Although LMP2A and LMP2B are similar in their structure,
the lack of the signaling amino-terminal domain in LMP2B
indicates distinct functions for these two proteins. Indeed, the
overexpression of LMP2B in Akata cells resulted in higher
mRNA expression of immediate-early and early lytic EBV
genes upon BCR cross-linking, whereas the overexpression of
LMP2A results in lower mRNA expression in these genes.
FIG. 5. LMP2B coimmunoprecipitates with LMP2A. Whole-cell protein lysates of Akata-LMP2B pool 2 (2B-2) and the Akata-vector control
were immunoprecipitated (IP) with anti-LMP2A (A). The IPs were separated on a SDS gel and immunoblotted (IB) against FLAG and LMP2A.
The heavy band in the LMP2A immunoblot represents the heavy Ig chain of the mouse antibody used for pull-down, whereas the lower, narrow
band represents the equal amount of LMP2A pulled down in 2B-2 and vector input lysates. (B) The input lysate of 2B-2 was split into IPs without
antibody, against c-myc, and FLAG and immunoblotted (three dilutions; 1, 0.2, 0.04) against FLAG. No unspecific pull-down with anti-c-myc
was observed due to the overexpression of FLAG-LMP2B. (C) The same IPs as those used in panel B were loaded on a SDS gel and
immunoblotted against c-myc to verify that the IP was working. The upper band (65 kDa) and the lower band (63 kDa) in the input lysate of 2B-2
represent two forms of c-myc.
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Moreover, LMP2B overexpression leads as well to production
of more EBV envelope protein gp350/220 and functional virus
than do LMP2A-overexpressing or control Akata cells upon
BCR cross-linking. These findings are compatible with our
previous observation that silencing of LMP2B in Akata cells
reduces the susceptibility of these cells to undergo EBV lytic
activation induced by BCR cross-linking (27). Thus, our cur-
rent and previous data provide evidence that LMP2B is in-
volved in the regulation of EBV switching from latent to lytic
infection EBV in B cells harboring the whole virus in its latent
form.
The overexpression of LMP2B did not result in spontaneous
switching of latent to lytic EBV. Nevertheless, the higher mag-
nitude of EBV lytic activation in LMP2B-overexpressing Akata
cells than that in control Akata cells upon BCR cross-linking
with similar doses of anti-IgG suggested that LMP2B exerts its
mode of action through lowering the required degree of BCR
cross-linking and thus BCR signaling needed. Since LMP2A
blocks BCR signaling (5, 6, 12, 15, 21, 29, 30, 35), we addressed
the fundamental question of whether the magnitude of EBV
lytic activation at given expression levels of the LMP2s de-
pends on the dose of anti-IgG required to cross-link BCR, i.e.,
the degree of BCR cross-linking. Indeed, although increasing
doses of anti-IgG elevated the levels of activation of lytic EBV
in LMP2A-overexpressing Akata cells until they reached a
plateau, peak levels of induced lytic EBV in these cells were
around at least 10-fold lower than in control Akata cells or
around 30- to 50-fold lower than in LMP2B-overexpressing
Akata cells. This result suggests that both endogenous and
overexpressed LMP2A is able to reduce BCR signaling very
effectively and cannot be completely counteracted, even by
saturated levels of anti-IgG added for cross-linking. Thus, the
amount of overexpressed LMP2B was able to decrease the
activity of endogenous LMP2A on BCR signaling but could
not abolish it completely in whole-EBV-containing cells.
An important question to be addressed was if there is an
interaction of LMP2A and LMP2B in Akata cells harboring
EBV and, if so, where the two isoforms of LMP2 colocalize.
The physical interaction between LMP2A and LMP2B was
verified by pulling down FLAG-LMP2B with endogenous
LMP2A. Our immunostaining results suggest an accumulation
of LMP2B in intracellular compartments and to a lesser extent
on the plasma membranes of Akata cells harboring whole
EBV. Lynch et al. (17) reported that transiently expressed
LMP2B localized to perinuclear regions and colocalized with
transiently or constitutively expressed LMP2A in EBV-nega-
tive BJAB cells or LCL B95-8CR, respectively. Studies using
HEK 293 cells overexpressing full-length or deletion mutants
of LMP2A revealed a clustering signal of LMP2A at the C
terminus leading to homodimerization (18). As LMP2A and
LMP2B share eight exons and the C terminus, Rovedo and
Longnecker (29) hypothesized that LMP2B colocalizes with
LMP2A, forming heterodimers, and subsequently negatively
regulates LMP2A activity, leading to decreased degradation of
FIG. 6. Overexpressed LMP2B and LMP2A colocalize before and after BCR cross-linking. (A) Negative control for secondary antibodies.
(B) To investigate where LMP2B and LMP2A localize, we transiently transfected Akata-LMP2A cells with FLAG-LMP2B (2A  Bt) and stained
for LMP2A and FLAG-LMP2B. To determine if there occurs a relocalization of LMP2A or LMP2B upon BCR cross-linking, we stained the
double-transfected Akata cells (2A  Bt) for FLAG-LMP2B and for LMP2A (C) and for BZLF1 and LMP2A (D) 3 h after BCR cross-linking
(E). DAPI, 4,6-diamidino-2-phenylindole.
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the tyrosine kinase Lyn. A more-recent study showed that
when tagged LMP2B was overexpressed in BJAB cells or HEK
293T cells, LMP2B was found exclusively in intracellular peri-
nuclear compartments (29, 37), a result which is in apparent
contrast with the results of the aforementioned study. When
LMP2B was truncated at any domain, it resulted in localization
to the cell surface. Based on these results taken together, one
can hypothesize that the major impact of LMP2B on LMP2A
takes place in endosomes, where it interferes either with the
activity of LMP2A and subsequent ubiquitination and degra-
dation of Lyn or with the trafficking of LMP2A back to the
plasma membrane.
An immunofluorescence analysis of LMP2A and LMP2B
suggested a colocalization of LMP2A and LMP2B in Akata
cells overexpressing both proteins. We detected a rather mod-
est shift of LMP2B and LMP2A into the cytosol, which sug-
gests their internalization after BCR cross-linking. Neverthe-
less, a large amount of both LMP2s remains detectable on the
plasma membrane, demonstrating an intact turnover process.
Moreover, this experiment allowed us to exclude the possibility
of misfolded and degraded protein in the endoplasmic reticu-
lum due to overexpression, as has been reported in earlier
studies (10, 19). It is known that LMP2A aggregates in lipid
rafts, assembling as a signalosome which enables a transient
interaction with the tyrosine kinases Syk and Lyn with a sub-
sequent block of the BCR signal (5–7, 15, 16, 21, 25, 26, 35).
One can hypothesize that after BCR cross-linking, the anti-
IgG/BCR complex is internalized together with closely located
lipid rafts and LMP2A signalosomes. If there is an additional
function of LMP2A in preventing the whole complex from
being transported again to the cell membrane, in this way
blocking continuous stimulation, one can hypothesize that
there is a loss of LMP2A at the cell surface and an accumu-
lation in endosomes located in the cytosol after BCR cross-
linking. LMP2B, which is found in cytosolic compartments,
may intervene in this step, disrupting homodimerized LMP2A
and restoring the turnover.
As demonstrated here for the first time, calcium mobiliza-
tion upon BCR cross-linking is dependent on the expression
level of LMP2B in EBV-harboring Akata cells. As expected
from previous reports (20–22), we observed virtually no cal-
cium mobilization in LMP2A-overexpressing cells upon BCR
cross-linking. By contrast, after transient transfection of
LMP2B into LMP2A-overexpressing Akata cells, calcium mo-
bilization after BCR cross-linking is increased to levels com-
parable to those observed for Akata cells overexpressing
LMP2B. Conversely, we measured a reduced calcium mobili-
zation in LMP2B-overexpressing Akata cells transiently trans-
fected with LMP2A. As transiently transfected vectors express-
ing the gene of interest lead to high levels of protein, the
dominant effect on the stably transfected Akata cells was pre-
dictable. Three different signaling pathways which are acti-
vated upon BCR cross-linking in Akata cells have been ana-
lyzed: (i) calcium mobilization through phosphatidylinositol
3-kinase, (ii) c-Jun N-terminal kinase activation through Syk
and Lyn signaling, and (iii) ERK1/2 phosphorylation through
the RAS protein (4). Nevertheless, whether LMP2B is involved
partially or throughout all these signaling cascades, taking a
key regulatory function upstream, remains unknown. Rovedo
and Longnecker showed recently that in the EBV-negative
B-cell line BJAB, ectopically expressed LMP2B decreases the
activity of LMP2A by alteration of the phosphorylation status
(29). Thus, LMP2B would function at an initial step of BCR
signaling to restore BCR signal transduction which was
blocked by LMP2A. As a more downstream read-out, they
chose to measure the calcium mobilization in BJAB cells upon
BCR cross-linking. As has previously been shown, the overex-
pression of LMP2A nearly abolished calcium mobilization (20–
22). According to the hypothesis of BCR signal restoration by
LMP2B, ectopic overexpression of both splice variants of
LMP2 together resulted in the phenotype of BJAB transfected
with vector control only.
LMP2B may have important functions not only in the mod-
ulation of latent and lytic EBV infection in tumor cells or
FIG. 7. LMP2B restores calcium mobilization in LMP2A-overex-
pressing Akata cells. Calcium levels were determined before and after
BCR cross-linking, and the kinetics were measured for 5 min. Upper
panels, calcium mobilization after BCR cross-linking in Akata control
cells and, as an additional control, in Akata cells with epigenetic
overexpression of an unspecific protein in the cytosol (see Materials
and Methods). Middle panels, calcium mobilization after BCR cross-
linking in Akata-LMP2B cells without (2B) and with (2B  At) tran-
siently transfected LMP2A. Lower panels, calcium mobilization after
BCR cross-linking in Akata-LMP2A cells without (2A) and with (2A
Bt) transiently transfected FLAG-LMP2B. Baselines were measured
just before BCR cross-linking. The percentage of responding cells was
calculated as described in Materials and Methods.
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memory B cells in the periphery. As was reported previously,
LMP2A is expressed in newly infected naı¨ve B cells before
latency is established and serves as a tonic signal for survival.
This scenario might be true for B cells with crippled or a total
loss of BCR expression, leading in the worst case to Hodgkin’s
lymphoma (11, 13). In contrast, if a naı¨ve B cell which has a
functional BCR is newly infected and receives the survival
signal, the additional signal of LMP2A might resemble in total
an activated BCR, forcing EBV to lytic infection. In the pres-
ence of LMP2B, the signal of LMP2A would be downregu-
lated, not leading to activated lytic EBV as was suggested
previously for high levels of LMP2A (32).
In conclusion, the data presented here provide evidence that
LMP2B is involved in the regulation of switching from latent to
lytic EBV in B cells harboring functional EBV. Based on our
present and previous findings for Akata cells (27) together with
observations made for the EBV-negative cell line BJAB (29),
we suggest that LMP2B has an impact on the activity of
LMP2A, resulting in increased susceptibility to induction of
lytic EBV infection through modulation of BCR and down-
stream signaling.
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7. Discussion
7.1 Induction of lytic EBV infection as treatment in clinics
Although there is good response to chemotherapy from BL and HL and as well encouraging 
prognosis after treatment, the side effects of using chemical agents are often dramatic. Thus, 
other approaches to eliminate these tumors were taken into account.
The fact, that most of these tumors contain EBV in the vast majority of the tumor cells (Table 
3), gave rise to the formulation of new possible tumor therapies. Prevention and treatment of 
EBV-associated tumors have focussed on counteracting the transforming effects of 
established latent EBV infection, i.e., the proliferation and expansion of EBV transformed 
cells in vivo using cytotoxic drugs, anti-B-cell antibodies, reduction of iatrogenic 
immunosuppression, or EBV-specific cytotoxic T lymphocytes. Unfortunately, these 
approaches are as well burdened with significant untoward effects including ample 
destruction of non-malignant cells, allograft rejection, life-threatening secondary infections, 
and technical as well as logistic hurdles. Furthermore, the efficiency is far from being 
satisfactory.
Another approach, i.e., the one to induce lytic EBV infection was investigated in this thesis. 
The DNA methyl transferase inhibitor (DNMTI) Zebularine has previously been shown to 
specifically induce cell death in tumor cells by demethylation of silenced tumor suppressor 
genes. We focused on the demethylation of silenced hypermethylated EBV genes to activate 
lytic infection by Zebularine which would have been an elegant way to kill all EBV-harboring 
tumor cells. Unfortunately, we could not show induction of lytic EBV infection in the BL cell 
line Akata using Zebularine, in contrast to control treatments with 5-Azacytidine resulting in 
cell death due to lytic EBV activation. Additionally, we positively verified demethylation 
activity of Zebularine by reactivation of E-cadherin expression which is normally silenced in 
Akata cells. Summarizing these findings, the promising new DNMTI Zebularine seems not to 
be an appropriate drug for the treatment of EBV-positive tumors. For more detailed 
information and discussion see section 6.1.
7.2 Induction of lytic EBV infection by LMP2B as treatment in clinics
Induction of lytic EBV infection via gene manipulation seems to be more promising than 
chemical induction as discussed in paragraph 8.1. In our studies, we could demonstrate higher 
lytic EBV infection in BL Akata cells after BCR cross-linking when LMP2B was 
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overexpressed in vitro (see sections 6.3). These results reveal a possible target for clinical 
therapy of EBV-associated tumors. However, there are many questions to be resolved first. 
Primarily, the effect of LMP2B has to be validated in a mouse model. Such a mouse model is, 
e.g., a SCID (Severe Combined Immuno Deficiency) mouse model in which human BL Akata 
cells overexpressing LMP2B are injected and grow due to the lack of an intact immune
response. After xenotransplantation, the growing tumor will be stimulated with anti-IgG as 
described in the in vitro experiments (section 6). If overexpression of LMP2B has the same 
effect in vivo as observed in vitro, the tumor growth should decrease and vanish due to lytic 
EBV infection and tumor cell death.
After this proof of principle in a mouse model, the next step would be to find an appropriate 
delivery system for LMP2B to the tumor in vivo. There are various options for the 
introduction of a foreign gene into a host and its integration into the genome. Among them (i) 
injection of naked or coated LMP2B with a gene-gun directly into the tumor tissue, (ii) 
infection of host cells with an attenuated virus expressing LMP2B, or (iii) completely 
artificial generated transport vehicles consisting of an outer membrane with surface receptors 
specific for B-cell homing and a ‘genome’ containing LMP2B and viral components for 
integration. The method of choice will depend on the progress in overcoming the technical 
hurdles which are still manifold in gene therapy.
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8. Conclusions and outlook
Taken together, the results presented in this PhD thesis shed new light on the regulation of 
latent and lytic EBV infection. Most importantly, new functions as a rheostat of LMP2A 
could be assigned to LMP2B and could be integrated into a model describing the development 
of EBV infected B-cells and B-cell derived lymphomas. The importance of a careful 
regulation of the expression levels of LMP2A and LMP2B depending on the physiological 
situation seems to be evident and shifting to either one or the other side of the balance 
determines the fate of the infected B-cell harboring EBV. So far, the factors which act as 
sensors for differential expression levels of LMP2B are not determined. It will be an 
interesting and challenging task to elucidate the regulatory mechanisms of the expression of 
LMP2B.
Finally, once the function of LMP2B is defined in vitro and in vivo, the step towards tailoring 
new therapeutic approaches in the treatment of EBV associated lymphomas using LMP2B as 
an inducer of lytic EBV infection comes into reach.
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